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Abstract 
 Recent advancements in high performance liquid chromatography (HPLC) have 
encouraged scientists to use multi-dimensional HPLC as a routine process analytical 
technology (PAT) tool for chiral drug development.1,2 Multi-dimensional HPLC techniques 
enable researchers to monitor multiple essential and sometimes, critical quality attributes 
(CQAs) in parallel. A unique three-column, four-dimension liquid chromatography system 
employing a two-loop heart-cut strategy is reported. The system is capable of re-circulating 
effluents from each dimension through a single detector and performing heart-cut operations 
using a programmable ten-port, two-position heart-cut valve. The first dimension of analysis 
measures peak ratios of products to reagents while the second dimension offers peak purity of 
the heart-cut material. The third dimension uses a chiral column to measure the enantiomeric 
excess (ee) of the chiral analyte and the effluent from the third dimension is re-analyzed via a 
fourth dimension to determine if any loss of chirality has occurred resulting from the analytical 
method itself. Performance of the setup was evaluated using the synthesis of Warfarin as a 
model chemical process. 
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1. Introduction 
 
1.1 Background 
 Quality control is an important aspect in the manufacturing industry wherein a rigorous 
set of procedures are implemented in order to monitor and maintain the quality of product 
output. Product quality is defined by a number of important attributes (e.g. yield, purity, 
particle size) with pre-set objectives or standards. Some attributes must meet rigorous standards 
set by various regulatory agencies (e.g., Food and Drug Administration (FDA) in the United 
States of America or Health Canada in Canada). These attributes are called quality attributes 
(QAs), and an example of such an important attribute is product purity.3 Pharmaceuticals, 
which have the potential to cause serious physiological harm, require extensive testing for 
product purity in order to meet regulatory standards.  On the other hand, there are other sets of 
attributes (e.g., product yield) that are key towards successful and profitable production of an 
active pharmaceutical ingredient (API).3 From a chemical manufacturer’s point of view, the 
objective is simple, to achieve maximum product yield with acceptable purity from a single 
production run. However, there is no direct correlation between product yield and product 
purity. The search for optimal production conditions is often conducted through empirically 
formulated experiments in-line with continuous monitoring via a process analytical technology 
(PAT) tool.4 PAT is defined as an in situ analytical tool capable of designing, analyzing, and 
controlling chemical processes through timely measurements of quality attributes to gain 
process understanding.3 The growing use of PAT in process optimization and in manufacturing 
has sparked interest in new technologies that will not only help with monitoring of a reaction 
process but also provide users with a feedback of data on the state of the reaction over time.4 
The practice of optimizing and monitoring a reaction process is resource-intensive and requires 
a significant amount of analytical support in order to screen through a relatively large number 
of conditions within a short period of time. There is not one PAT tool applicable for all 
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chemical applications, and so multiple, appropriate analytical tools may have to be coupled to 
provide timely measurements of chemical processes.3 As the number of analytical tools that 
need to be coupled increase in number, automation must be incorporated to provide analytical 
support and ensure reliability of the operation.2 Chemical analysis, which deals with the science 
of measurement to evaluate the fate of a scientific experiment, plays a key role in this pursuit 
of ideal strategies for chemical production.  
 High Performance Liquid Chromatography (HPLC) is one of the most widely-used 
analytical tools for chemical analysis.4–6 In HPLC, an analytical sample is injected onto a 
chromatographic medium, and a liquid mobile phase is used to separate various chemical 
components which are then sent to a suitable detector one component at a time to separate 
reaction components and to assess purity of a particular component (i.e., the HPLC purity).  
HPLC technologies have advanced significantly over the decades and the analysis has become 
relatively complex, but routine.4–6 The analysis has become complex especially when analyses 
are conducted on complex mixtures containing a large amount of closely related compounds 
(i.e. similar fragmentation). In HPLC, such complex mixtures would display poor resolution in 
the chromatogram; furthermore, for unstable compounds capable of further reacting, or 
degrading on-column, the analysis may not provide meaningful output of data (i.e. in 
measurement of HPLC purity) and may require off-line purification techniques that may extend 
to long periods of time. In addition to this, analytical methods often call for elaborate 
preparation of a sample prior to injection. This is observed in chemical reactions containing 
metal; the metal can chelate towards the stationary phase and hinder separation of the reaction 
mixture. Sample preparation can be tedious and time consuming, and often the preparation 
varies depending on what type of purity analysis is required in a particular manufacturing 
process. For example, if the targeted component is a chiral molecule, compound purity as well 
as optical purity assessment is necessary in order to fully understand the process. 
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Unfortunately, data for these QAs (i.e., the HPLC purity and the optical purity) do not originate 
from a single analytical experiment. For optical purity measurements, one must remove all 
achiral components from the sample prior to performing a chiral HPLC analysis.7 Quite often, 
off-line chromatographic purifications (e.g. column chromatography) are conducted for each 
and every chemical synthesis to obtain sufficient quantities of clean target materials before 
chiral analysis can be conducted.7 This process is iterative, time-consuming, and requires 
multiple layers of analytical validation protocols to confirm if the HPLC purity of the chiral 
injectable is satisfactory for further chiral analysis. 
  Multi-dimensional chromatography, which was first developed to analyze target 
analytes using multiple chromatographic media, has emerged as an important tool for the 
manufacturing of chiral pharmaceuticals.1,8,9 A chromatographic dimension refers to an 
analysis step where information on a QA or verification of an output QA can be obtained (i.e.  
it is an analytical space where chromatographic separations and analyses are enabled). These 
analyses can be conducted through one or more columns and one or more detectors. Significant 
amount of proteome analysis applications have relied on multidimensional separation 
protocols10–15; with few other applications expanded towards enantioseparation of 
pharmaceutical drugs.1 Modifications were made to the original multi-dimensional platform to 
not only increase the resolution of chromatographic separations, but also to acquire data for 
various types of QAs from a single chromatographic experiment. The ability to collect data for 
multiple QAs from a single injection is extremely useful, especially for drug manufacturing 
where more than half of the drugs currently in market are chiral compounds, and nearly 90% 
are administered as racemates.8 In drug manufacturing, the product purity and optical purity 
both play an equal role in defining the fate of the manufacturing process. The multi-
dimensional technology for drug analysis employs an achiral chromatographic medium for first 
dimension analysis and a chiral chromatographic medium (contains a single enantiomer of a 
 4 
chiral compound to form a Chiral stationary phase (CSP)) for second dimension analysis). In 
order to conduct a multi-dimensional chiral analysis for a target chiral analyte, the selective 
transfer of the chiral analyte from the achiral chromatographic medium to the chiral 
chromatographic medium must be facilitated. When an analyte is sent directly to a detector 
from an achiral chromatographic medium, the output data constitutes the first dimension 
analysis, and provides information on product purity, a QA, and if an internal standard is used, 
product yield, a key QA for the process. When a targeted fraction from the first dimension 
analysis is diverted to the same detector or a second detector via a chiral chromatographic 
medium, data for the second dimension analysis, which contains the chiral purity information, 
is collected. The technique involved in the process of transferring a selected fraction from the 
first dimension effluent to the second-dimension stream is known as the ‘heart-cut’ technique.16 
A heart-cut protocol utilizes a transfer valve which first traps a portion of the effluent from the 
first-dimension stream in a loop and then delivers the trapped sample from the loop to the 
second-dimension stream. 
 Veuthey and coworkers reported a liquid chromatography-mass spectrometer (LC-MS) 
system equipped with a heart-cut mechanism (Figure 1) in 2003 for the analysis of seven 
process related substances in tablets containing cetirizine as the active ingredient.17 The authors 
did not use a conventional two-dimensional chromatography platform for this work. The 
authors observed that repeated injections of high concentrations of cetirizine deteriorated the 
performance of the MS detector.17 Their heart-cut design was employed to reduce interference 
of the highly concentrated cetirizine by channeling selective portions of the post-
chromatography stream to two detectors in parallel located downstream of the heart-cut 
valve.17 A schematic outline of the design is shown in Figure 1. Once the heart-cut operation 
of a chosen segment was completed, there was no provision to recycle the material and repeat 
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the heart-cut operation in the event the heart-cut operation failed to isolate the chosen segment 
in desired purity from the first heart-cut attempt. 
 
Figure 1: a) Heart-cut design by Veuthey and coworkers for the analysis of cetirizine tablet 
ingredients with heart-cut valve in communication with UV detector. b) Heart-cut design by 
Veuthey and coworkers for the analysis of cetirizine tablet ingredients with heart-cut valve in 
communication with MS detector. Legends: P = HPLC pump, I = Injector, C1 = 
Chromatographic medium, VH = Heart-cut valve, LP1= loop 1, D1 = First detector (UV), D2 
= Second detector (MS), W = Waste  
 A two-dimensional analytical platform, comprising of an achiral first dimension and a 
chiral second dimension, was developed by Natalini and his group to quantify dansylated 
amino acid (D-AAs) levels in cows with mastitis.18 In their design, the first dimension analysis 
was performed for the separation of D-AAs and the second dimension analysis was performed 
for the chiral separation of a particular portion of the first dimension effluent.18 A six-port 
heart-cut valve, which was responsible for trapping a portion from the first-dimension stream 
and transferring the trapped material to the second-dimension stream, was located downstream 
of a detector responsible for the first dimension analysis.18 A schematic outline of the design 
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is shown in Figure 2. A second detector solely responsible for acquiring data for the heart-cut 
sample was located downstream of the heart-cut valve. The fate of the heart-cut operation was 
only known after the heart-cut sample reached the second detector. The design did not offer a 
provision to re-circulate the heart-cut sample in the event the heart-cut operation failed to 
isolate the desired portion of the effluent from the first-dimension run. One must perform 
multiple injections and run the entire sequence of both dimension runs in order to perfect the 
heart-cut operation.  
 
Figure 2: a) Two-dimensional design by Natalini and coworkers for the analysis of dansylated 
amino acids with heart-cut valve loop in communication with first dimension analysis. b) Two-
dimensional design by Natalini and coworkers for the analysis of dansylated amino acids with 
heart-cut valve loop in communication with second dimension analysis. Legends: P1 =HPLC 
pump for the first-dimension chromatography, P2 = HPLC pump for the second-dimension 
chromatography, I = Injector, C1 = Chromatographic medium for the first dimension, C2 = 
Chromatographic medium for the second dimension, VH = Heart-cut valve, LP1=loop 1, D1 = 
Detector for the first dimensional analysis, D2 = Detector for the second dimensional analysis, 
W = Waste  
Chetwyn and coworkers also reported a design wherein multi-dimensional analysis was 
carried out using a heart-cut valve.19 A schematic outline of their design is shown in Figure 3. 
In this setup, the first dimension analysis was done using a first-dimension detector placed 
before the heart-cut valve.19 Following the heart-cut valve operation, the second dimension 
analysis was done using a dedicated second detector.19 The heart-cut valve, which was 
equipped with two sample holding loops, was capable of diverting multiple heart-cut samples 
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to the second detector.19 If the heart-cut method failed to capture a particular portion of the 
effluent from the first-dimension run (i.e., if the purity of the heart-cut material is less than 
100%), a second injection would be needed to rectify the heart-cut operation as there is no 
provision to bring back the heart-cut sample post-detection. Furthermore, if any comparison of 
data between the first and the second dimension analysis were to be made, calibration of the 
two detectors would be required in order to ensure consistency. 
 
Figure 3: a) Two-dimensional design by Chetwyn and coworkers with heart-cut valve in 
primary configuration for first dimension analysis. b) Two-dimensional design by Chetwyn 
and coworkers with heart-cut valve in secondary configuration for second dimension analysis. 
Legends: P = HPLC pump, I = Injector, C1 = Chromatographic medium for the first dimension, 
C2 = Chromatographic medium for the second dimension, VH = Heart-cut valve, LP1= loop 
1, LP2= loop 2, LP3= loop 3, D1 = First detector (UV), D2 = Second detector (MS), W = 
Waste 
 Scientists from Waters Corporation have developed a multi-dimensional platform 
suitable for chiral drug analysis (Figure 4). The design uses a set of detectors and pumps 
dedicated for each of the two dimensions. The design is also equipped with a ‘trap and purge’ 
mechanism for post heart-cut sample purification.20 However, the detector for the second 
dimension is still at the terminal point of the multi-dimensional analysis.20 The success in the 
operation of the heart-cut mechanism is reliant on the chemical properties of the trap since 
there is no provision to re-circulate the heart-cut fraction back into the second dimension 
chromatographic medium. One must perform multiple injections and run the entire sequence 
of both dimension runs in order to perfect the heart-cut operation.  
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Figure 4: a) Two-dimensional design by Waters Corporation with primary heart-cut valve in 
position 2. b) Two-dimensional design by Waters Corporation with primary heart-cut valve in 
position 1 for peak trapping in trap column. c) Two-dimensional design by Waters Corporation 
with secondary heart-cut valve in position 1. Legends: P1 =Quaternary Solvent Manager, I= 
Sample Manager, P2 = Isocratic Solvent Manager, P3= Binary Solvent Manager, C1 = 
Chromatographic medium for the first dimension, C2 = Chromatographic medium for the 
second dimension, Trap= Trap column, VH1 = Primary Heart-cut valve, VH2 = Secondary 
Heart-cut valve, D1 = Detector for the first dimensional analysis (Photodiode Array Detector), 
D2 = Detector for the second dimensional analysis (Tunable Ultraviolet Detector), Mixer= 
Mixing unit, W = Waste, Boxed ports are not in use. 
 Pedrazolli Jr. and coworkers investigated chiral separations of pantoprazole in human 
plasma through a multidimensional HPLC coupled with a restricted access media (RAM) 
bovine serum albumin (BSA) column and chiral polysaccharide column.21  The setup shown 
in Figure 5 offered a means of analyzing biological fluids while reducing overall sample 
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preparation and analysis time.21 The RAM column was coupled to prevent the elution of 
unwanted proteins towards analysis (i.e. solid- liquid extraction to prevent access of matrix 
components while retaining desired hydrophobic analytes).21 In the following setup, the 
RAM column acted as a heart-cut valve and delivered matrix components towards waste and 
retained analytes were eluted out towards the chiral column.21 Similar to the other examples 
above, the setup has no provision of ensuring that the injectable sent towards chiral analysis 
is sufficiently pure.  
 
Figure 5: a) Two-dimensional design by Pedrazolli Jr. and coworkers using a RAM column for 
enantiomeric determination of pantoprazole in fluid communication with RAM. b) Two-
dimensional design by Pedrazolli Jr. and coworkers using a RAM column for enantiomeric 
determination of pantoprazole in fluid communication with chiral column Legends: P1 =HPLC 
pump for the first-dimension chromatography, P2 = HPLC pump for the second-dimension 
chromatography, I = Injector, RAM = restricted access media column, D = Detector for the 
second dimensional analysis, W = Waste 
 Nik P. Chetwyn and coworkers have developed an automated online multi-heart 
cutting two dimensional HPLC system with UV-charged aerosol MS detection.22 The 
platform shown in Figure 6 was developed to resolve the challenging issues present in 
pharmaceutical impurity analysis.22 Their setup comprises of a first dimension, primary 
column in-line to a second dimension with six orthogonal columns along with an 
intermediary pair of switching valves with multiple loops for multiple heart-cutting of 
peaks.22 They carried out analysis on Genentech proprietary developmental drugs to establish 
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a proof of concept to their setup.22  However, the detector for the second dimension is still at 
the terminal point of the multi-dimensional analysis, and so the setup has no provision of 
ensuring that the injectable sent towards further analysis is sufficiently pure.
 
Figure 6: a) Two-dimensional design by Nik P. Chetwyn and coworkers using an UV-charged 
aerosol MS detection in position 1 for first dimension analysis. b) Two-dimensional design by 
Nik P. Chetwyn and coworkers and coworkers using an UV-charged aerosol MS detection in 
position 2 for second dimension analysis (with option of second dimension column from C1-
C6). Legends: P1 =HPLC pump for the first-dimension chromatography, P2 = HPLC pump for 
the second-dimension chromatography, I = Injector, C1 = Chromatographic medium for the 
first dimension, C1-C6 = Chromatographic mediums for the second dimension, D1 = Detector 
for the first dimensional analysis, D2 = Detector for the second dimensional analysis, W = 
Waste, Boxed ports are not in use. 
 Shalliker and coworkers developed a multidimensional reversed-phase HPLC for 
isolation of active constituents from a crude extract of Clerodendrum floribundum R. Br.23 
Their system shown in Figure 7 comprises of two dimensions of analysis through two 
columns run through an isocratic solvent method. The two dimensional HPLC’s heart-cut 
protocol was employed via two six port two position valves intermediary to both dimensions 
of analysis.23  Similar to the above examples, the detector for the second dimension is at the 
terminal point of the multidimensional analysis, and so the setup has no provision of ensuring 
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that the injectable sent towards further analysis is sufficiently pure. 
 
Figure 7: a) Two-dimensional design by Shalliker and coworkers using two six-port two 
position valves for heart-cutting in position 1 first dimension analysis. b) Two-dimensional 
design by Shalliker and coworkers using two six-port two position valves for heart-cutting in 
position 2 second dimension analysis. Legends: P1 =HPLC pump for the first-dimension 
chromatography, P2 = HPLC pump for the second-dimension chromatography, I = Injector, 
C1 = Chromatographic medium for the first dimension, C2 = Chromatographic medium for the 
second dimension, D1 = Detector for the first dimensional analysis, D2 = Detector for the 
second dimensional analysis, W = Waste, Boxed ports are not in use. 
It is important to note here that the quality of the multi-dimensional chiral analysis 
depends on the accuracy of the heart-cut operation. For example, if the heart-cut method fails 
to trap the single target analyte of the first-dimension effluent from the achiral dimension, more 
than two peaks, that is two peaks originating out of the chiral separation of enantiomers in 
addition to other impurities originating from the imperfect heart-cut event, are likely to appear 
in the chiral dimension, which would make the chiral dimension analysis cumbersome and 
possibly error-prone. There is need for a multi-dimensional chromatographic setup that can 
verify completion of the heart-cut operation before the analysis for the chiral dimension takes 
place. The promise of such a chromatographic setup that would allow scientists to channel the 
targeted effluent of one dimension into another with a “confirmed” purity of the injectable, is 
enormous. This would allow researchers in screening facilities to reduce the risk of making 
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errors while generating valuable data on synthetic methods.  However, incorporation of such a 
concept calls for the ability to re-circulate a selected portion of the effluent into a 
chromatographic medium equivalent to the first dimension so that the verification of the heart-
cut operation could take place.  
Another common dilemma associated with multi-dimensional chiral analysis stems 
from the possibility of on-column degradation (or racemization) during chromatographic 
separation. Racemization of a chiral center in the molecule of interest may occur under 
chromatographic conditions and the current state of the art in the field of multi-dimensional 
chromatography does not offer a solution to such chromatographic artefacts. Chemists often 
resort to the highly time-consuming and tedious task of synthesizing optically pure samples of 
each enantiomer of a target analyte either using an available synthetic procedure or through 
off-line purification techniques. The practice of making enantiomerically pure analytical 
samples for bulk manufacturing of the same chiral molecule often comes at a high cost 
primarily due to the expensive research and development work. The ability to isolate either of 
the two enantiomers from the chiral dimension stream and re-circulate one of the two 
enantiomer peaks back into the same chiral chromatographic medium would be extremely 
valuable. If an enantiomer were recirculated from the second chiral chromatographic run and 
produces more than one peak in the chromatogram, this would provide users with evidence of 
on-column degradation. The ratio of peak areas from the second chiral dimension could 
potentially allow for quantification of the chromatographic artefact from the first chiral 
dimension analysis. 
 A multi-dimensional chromatographic system that would allow any portion of the 
effluent from any chromatographic medium to be re-circulated through the same, or a different 
chromatographic medium for any number of times would be valuable. For example, when 
equipped with a heart-cut mechanism, such a setup would allow chemists to verify the accuracy 
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of the heart-cut operation by recycling a target analyte through the appropriate 
chromatographic media.  
1.2 Aims and Objectives 
 The goal of the project was to design and test a multi-dimensional chromatographic 
platform which allows for the measurement of multiple QAs from a single injection. 
Specifically, the multi-QA analysis was to be tested for the synthesis of chiral compounds.  
 A preliminary two-dimensional HPLC setup (beta-platform) platform was constructed 
with the aim of providing information on the heart-cut valve switching mechanism. The first 
objective of the project was to investigate the basic two-dimensional HPLC capabilities for 
heart-cutting and valve switching without co-elution of the mobile phases.  
 The second objective was to implement the re-circulation function of separated 
effluents representing a specific peak in the multi-dimensional HPLC system.  
 The third objective was to integrate the analytical platform to an existing flow reactor 
system to test the effectiveness of the new multi-dimensional design in the flowed synthesis of 
chiral compounds.24–28 Ultimately, the design was to be tested with real-life drug syntheses to 
see if the new design shows promise to be a multi-QA PAT tool.3 
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2. Results and Discussion 
2.1 Multi-QA Analysis  
 In response to the highlighted notion of employing a multi-dimensional setup capable 
of recirculating target analytes through different chromatographic media, a multi-dimensional 
chromatographic setup coupled with heart-cut capabilities was developed. The multi-
dimensional chromatographic setup would allow for the separation of an analytical mixture 
using a chromatographic medium and the isolation of a portion of the effluent in a two-position 
heart-cut valve following the first dimension analysis by a detector located upstream of the 
valve. The valve, which is capable of establishing fluid communications with multiple numbers 
of chromatographic media and a detector downstream of the chromatographic media, would 
send a selected portion of the effluent from the first dimension chromatographic medium to a 
new chromatographic medium that is identical in stationary phase to the first dimension 
chromatographic medium. The analysis by the second chromatographic medium would provide 
information on the accuracy of the heart-cut operation. This is the second dimension of 
analysis, which would act as a qualifying run for the subsequent chiral analyses in the proposed 
multi-dimensional setup. Once the heart-cut operation was judged successful (i.e. single peak 
observed), the heart-cut valve would channel the effluent into a chiral chromatographic 
medium to provide optical purity of the injected sample. This is the third dimension of analysis 
for the proposed design. The effluent from the third dimension analysis could be further 
recycled via the same or an identical chiral dimension to inspect if any on-column degradation 
took place during the third dimension analysis. This is the fourth dimension of the proposed 
multi-dimensional analysis. In our lab, this analytical protocol employing the analysis of 
multiple QAs along with in-line validation of the heart-cut process is called multi-QA analysis. 
A work-flow of this multi-QA analysis protocol incorporating various chromatographic 
dimensions and their purposes are shown in Figure 8.  
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Figure 8: Schematic drawing of proposed novel multi-QA analytical protocol  
The schematic drawing of the proposed multi-dimensional chromatographic platform 
is shown in Figure 9. Sample injection would be facilitated via an auto sampler that would 
direct the sample into an injector valve (VI). This injector valve would be in fluid 
communication with a downstream column selector valve (VS), which would direct samples 
through a host of chromatographic media (e.g., C1, C2 and C3). The injected sample would be 
first flowed into C1, which would act as the first dimension chromatographic medium and 
channel the separated effluent stream to a detector (D) located downstream of C1 via VS. This 
completes the first dimension analysis, which would give a measurement of peak areas of the 
product, reagents, and any byproducts as recorded by detector D. A heart-cut valve (VH), which 
is located downstream of D receives the effluent from the first dimension analysis and would 
trap a selected portion of the effluent for subsequent analyses. Valve VH would channel the 
trapped sample to chromatographic medium C2, which is identical in stationary phase to 
chromatographic medium C1. The same detector would be used to confirm if the heart-cut 
operation by valve VH successfully trapped a single peak of interest. In other words, the second 
dimension analysis offers peak purity of the heart-cut sample. In the event the heart-cut 
operation failed to isolate a single peak of interest, the design is capable of recirculating the 
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unsuccessfully heart-cut sample back into valve VH and eliminating peaks that are not of 
interest. The new heart-cut sample can be recycled through chromatographic medium C2 again 
to re-assess the performance of the second heart-cut step. In other words, the design is such 
that any particular chromatographic medium downstream of valve VH (e.g., C2 or C3 in Figure 
9) could receive the same heart-cut sample a several times in order to troubleshoot the heart-
cut operation. The strategy could fail however, if the intensity of the observed response from 
detector D diminishes below the recordable limit of the detector. The stated eventuality might 
occur if sample is lost due to binding onto the stationary phase, or if the heart-cut loop is not 
overfilled resulting in the analyte being diluted or if the analyte is too broad, in peak width, 
resulting in unsuccessful trapping of the entire contents of the peak in the loop. Once the 
operation in the heart-cut method is deemed satisfactory, the same heart-cut valve streams a 
desired portion of effluent from the second dimension analysis, the target chiral analyte at this 
point, towards the chiral chromatographic medium to undergo a chiral separation to give two 
peaks, each representing a single enantiomer (if both are present) (C3 in Figure 9). The detector 
would measure the respective peak areas to provide optical purity (or % enantiomeric excess 
(%ee)) of the target analyte. This is the third dimension of the entire multi-dimensional 
analysis. The selected portion of the effluent (single targeted enantiomer) from the third 
dimension would be then diverted back to the same chiral chromatographic medium (C3) by 
valve VH and re-analyzed to determine if any degradation (i.e., racemization) of the 
stereocenter has occurred during the third dimension analysis. This constitutes the fourth 
dimension of analysis. In short, this unique design provides information on product purity 
through the first dimension analysis and optical purity through the third dimension analysis. 
Intermediary to these dimensions, the second dimension analysis confirms the quality of results 
to be acquired from the chiral analysis by confirming the purity of the heart-cut sample prior 
to its injection into the chiral dimension. The fourth dimension also confirms the quality of 
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data from the chiral analysis by verifying the stability of the corresponding enantiomers under 
the chiral chromatographic conditions. A step-by-step schematic outlining the valve actuation 
and entire multi-QA analytical protocol can be found in the Experimental on page 73. 
 
  
Figure 9: Novel multi-dimensional HPLC analytical platform with heart-cut capability. 
Legends: P = HPLC pump, I = Injector, C1 = Chromatographic medium for the first dimension, 
C2= Chromatographic medium for the second dimension, C3= Chromatographic medium for 
the third dimension, VH = Heart-cut valve, D = Detector (DAD), W = Waste, LI= Injector 
valve loop, LH1= Heart-cut valve loop 1, LH2= Heart-cut valve loop 2. 
The new design is expected to provide a tool for multi-dimensional chiral analysis. The 
ability to re-circulate a selected portion of the effluent from one dimension to the other 
dimension for a number of cycles would allow for exhaustive analysis of samples that may 
have a limited supply (e.g., samples labelled with radio-isotopes or samples with hazardous 
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properties). Furthermore, any heart-cut sample can be re-circulated through the same 
chromatographic medium for a multiple number of times depending on the recovery of sample 
from each chromatographic run. This would allow a new mechanism to perfect a heart-cut 
method until the method is declared optimal based on a live feed from the detector. The heart-
cut method is dependent on several parameters that control the heart-cut valve’s actuation times 
for effective heart-cutting of a target analyte. The valve has to switch back and forth between 
load and inject positions to successfully trap a selected portion of the effluent. The actuation 
times cannot be set absolute, but have to be adjusted relative to an absolute reference time 
which is the time of injection.  The absolute reference time is necessary in analysis as it 
establishes a starting point from which retention time of each eluting peak can be measured 
from. This measure of retention time tR is important as based on retention time of a targeted 
peak, a delay time is to be applied in the controller software so that the heart-cut valve starts to 
receive the selected portion of the effluent in the heart-cut loop by switching to the load 
position. This time is termed as the ‘open delay’. The time when the valve must switch back to 
its original position (i.e., the inject position) is termed as the ‘close delay’. The difference 
between these two delay times constitutes the time during which the heart-cut valve resides in 
the load position. This time is a function of various chromatographic conditions of the previous 
dimension run, which during the heart-cut operation, remains active. Two parameters that 
primarily impact the fate of the heart-cut process are the flow-rate of the mobile phase of the 
active dimension run and the peak-width of the targeted peak of interest. There are also 
secondary influences, which are of no less importance for a successful heart-cut, including the 
laminar nature of flow in chromatographic flow-paths and the post-detection rate of diffusion 
of the target analyte plug in the mobile phase during its journey from the detector to the heart-
cut valve. The back-pressure from the chromatographic media in question is also expected to 
play a role during the actuation of the heart-cut valve. It is important to note that the detection 
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time needs to be offset by a time based on the swept volume between the detector and the heart-
cut valve so the actuation of the heart-cut valve happens exactly when the targeted portion of 
the effluent enters the heart-cut valve. 
In comparison to conventional analytical protocol along with other multidimensional 
analytical protocol, a multi-QA analytical method developed through a multidimensional 
HPLC provides effective timely measurements of quality attributes with a confirmation of 
purity (Table 1). The disadvantages noted will soon be addressed in the future, wherein our 
detector will be treated as a live feed detector offering live feed monitoring capabilities along 
with valve actuations of peaks on a peak area basis (i.e. peak trapped within a range of time 
once its magnitude/ peak height exceeds a set threshold). Furthermore, the largest disadvantage 
currently present for a variety of multidimensional applications is the difficulty to switch 
directly between a reverse phase mode of separation in the first dimension to a normal phase 
mode of separation in the second dimension or vice versa. It is important to maintain the solvent 
strength across both dimensions of analysis in multidimensional applications and employ a 
gradient elution method to prevent co-elution of the mobile phase. 
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Advantages Disadvantages 
• Reaction monitoring 
• Adjustment of Heart-cut protocol 
• Multivariate analysis of multiple 
quality attributes 
• Recycling through same or different 
dimensions of analysis 
• Compliance with other stationary 
phase media and other detectors 
• Intelligent System Controller 
Software 
• Priming protocol prevents co-elution 
of mobile phase (i.e. ensures safety of 
column) 
• Actuation on time basis  
• No live feed detection 
• Maintenance of solvent strength 
through all dimensions 
Table 1: Advantages vs. Disadvantages of our multi-QA analytical protocol through a 
multidimensional HPLC 
The performance of the setup was initially evaluated using a Buchwald-Hartwig 
amination reaction in flow. The sampling was done online using an online sampling mechanism 
developed in the Organ laboratory.24–28 Later, synthesis of Warfarin was used as a model chiral 
drug synthesis to evaluate the performance of the proposed multi-dimensional design. The 
chiral drug syntheses were performed under batch conditions and the samples were analyzed 
off-line using the proposed multi-dimensional HPLC system.  
2.2 Development of a first-generation platform with a heart-cut mechanism 
(Beta-model) 
 
  The first step towards building the proposed multi-dimensional chromatographic platform 
(Figure 9) was to examine chromatographic properties (e.g., retention time, peak area, width, and 
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shape) of peaks in the new dimension when a selected portion of the chromatographed effluent from 
one chromatographic medium is re-circulated through the same or a different chromatographic 
medium. The selected effluent would travel through various chromatographic modules, which could 
consist of flow-paths of vastly different internal diameters (e.g., typical movable slits inside the rotor 
of a heart-cut valve would have an internal diameter of 0.4 mm and a typical flow-path of a detector 
flow-cell would have a path length of 10 mm) during the multi-dimensional operation. The back-
pressure from different chromatographic media could also be different depending on the porosity of 
the stationary phases and the flow-rate of the mobile phase. A lack of uniformity in chromatographic 
flow-paths will result in variations in back-pressure that may cause turbulence and pressure 
fluctuations throughout analysis. Furthermore, this also could lead to undesirable peak broadening due 
to Brownian motion. A rudimentary two-dimensional HPLC (2D-HPLC) setup equipped with a heart-
cut mechanism was first built as a beta-platform to investigate the behavior of when injected samples 
undergo a heart-cut process of a single peak of interest from one dimension towards another. A 
schematic diagram of the rudimentary 2D-HPLC setup is shown in Figure 10.  
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Figure 10: Rudimentary 2D-HPLC setup (beta-platform) for preliminary investigation. The 
insert shows the second position of the heart-cut valve. Legends: P = HPLC pump, VI=Injector 
valve, VS = Column selector valve, VH = Heart-cut valve, I = Injector port, LI = Injection 
loop, LH = Heart-cut loop, LB = Bypass loop, C1 = First dimension chromatographic medium, 
C2 = Second dimension chromatographic medium, D = Detector, W = Waste 
In the beta-platform, a quaternary HPLC pump (P) was connected to a six-port two-
position (load and inject) injector valve (VI), which remained in fluid communication with a 
fourteen-port six-position column selector valve (VS). The injector valve was equipped with a 
standard injection loop (LI), capable of receiving analytes at the load position of VI and 
channeling the injected analyte plug toward VS from the inject position. Valve VS was capable 
of diverting fluids through one of the six available flow-paths; each flow-path comprised of a 
set of inlet and outlet ports. Fluids travel to and from the valve via the central inlet and outlet 
ports (shown in blue and pink respectively, Figure 10). Two chromatographic media (HPLC 
columns C1 and C2) were placed in two of the six available flow-paths of VS in accordance with 
the connectivity illustrated in Figure 10 (shown in red for C1 and in green for C2). The 
remaining four flow-paths were not used (shown in boxed black circles, Figure 7) at this point. 
A ten-port, two-position valve (VH), which was used to perform heart-cut tasks, was situated 
downstream of the central outlet port of the column selector valve (VS). Column C1 was 
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connected to the first set of inlet and outlet ports of VS via two adjacent ports on valve VH 
(Figure 10). On the other hand, column C2 was connected to the second set of inlet and outlet 
ports of VS via a heart-cut loop (LH) on VH. A variable wavelength photo diode array UV 
detector (D) was connected downstream of the central outlet of VS. When VS set fluid 
communication between pump P and C1, the fluid moved from VI to VH via C1. Valve VH was 
capable of channeling effluent from C1 directly to detector D in the valve-position shown in 
Figure 10. Data acquired by detector D constitutes the data for the first dimension analysis.  
Only eight out of ten ports of valve VH were used for this rudimentary 2D-HPLC 
design. Two loops were mounted on VH (LH and LB, shown in green and black). When VH was 
rotated (insert in Figure 10), a portion of the effluent from C1 flowed into loop LH, which was 
the heart-cut loop. During this time, C2 maintains fluid communication with valve VS using the 
second loop LB, which is a bypass loop. When VH was rotated back to its original position, a 
portion of the fluid was isolated in LH. At this point, VS was rotated to establish fluid 
communication between pump P and C2, and the fluid from LH moved towards C2. The effluent 
from C2 reached the same detector via VS. Data collected by detector D from this stream 
constitutes the data for the second dimension analysis.  
Detector D was the terminal point of this beta-design. There was no provision for the 
effluent to travel through the detector and re-enter into the stream selector flow-paths for 
further analysis.  As mentioned before, the setup was built to assess any impact that peak 
trapping could have on peak properties, which in turn, could affect analytical requirement such 
as good run-to-run reproducibility. Separate injections were made to analyze a target analyte 
from the first and the second-dimension chromatograms. In some cases, the heart-cut valve 
was physically disconnected from the flow-path to assess the peak broadening effects during 
the heart-cut step. 
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Figure 11: A schematic representation of the ‘open delay’ and ‘close delay’ time functions with 
respect to valve VH positions. The arrows indicate the direction of active flow during the heart-
cut operation. Legends: VS = Column selector valve, VH = Heart-cut valve, C1 = First 
dimension chromatographic medium, C2 = Second dimension chromatographic medium, LH 
= Heart-cut loop, LB = Bypass loop. 
 In order to trigger the actuations (i.e., rotation of valve) of VH, a valve switching 
protocol was implemented in the controller software. The firmware for the heart-cut operation 
involved two parameters: ‘open delay’, a time-function, is set relative to the time of the 
injection of an analyte at VI, and ‘close delay’, a second time-function, is set relative to the 
open delay time. In other words, the open delay function exposes the heart-cut loop to the first-
dimension (C1) stream. The close delay function on the other hand, sets a time to rotate the 
heart-cut valve back to its initial position and isolates a portion of the first-dimension stream 
in LH. Figure 11 illustrates the fluid movement during the execution of the open and close delay 
functions in the firmware. In an ideal world, these two time-functions can be calculated based 
on a simple mathematical relationship between flow-rate of the mobile phase for the 
chromatographic run in question and swept volumes of relevant flow-paths between detector 
D and the heart-cut valve VH. Detector D measures retention time, a time at which a certain 
peak of interest reaches the point of detection in D. When a calculated off-set time is subtracted 
from the retention time value, the time at which a targeted peak reaches VH, can be estimated.  
An arbitrarily chosen analyte (2-chloropyridine) was used to examine this hypothesis. A 
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sample was injected in C1, a reverse phase C18 HPLC column, to measure the retention time 
of the analyte from the first dimension analysis. A separate second injection of the same analyte 
was made, this time with the heart-cut valve actuated to trap a portion of the first-dimension 
stream in a 10 µL heart-cut loop (LH). Valve VH and VS were rotated appropriately to move the 
heart-cut sample from LH to detector D via C2. For the preliminary study, C2 was also an 
identical C18 reverse phase HPLC column. The outcome of the heart-cut method was evaluated 
based on the presence or absence of the analyte peak in the second-dimension chromatogram. 
Unfortunately, the peak was not observed in the second-dimension chromatogram. Small 
volume loops, which often come with narrow internal bore size, are ideal for trapping a narrow 
segment of the first-dimension stream. However, the estimation of open and close delay 
functions proved to be extremely difficult using small volume loops. Alternatively, a larger 
sample holding loop (100 µL), which is commercially available only in wider bore sizes (0.02” 
bore) can be used for heart-cut purposes. It is important to note here that the wider bore flow-
path could affect the quality of the second-dimension data. In using a wider bore size and larger 
loop volume there is the potential risk of transferring over peaks aside from the target analyte; 
in contrast to this, a smaller loop volume and narrower bore size, would heart-cut only a 10µL 
portion of the target peak towards the second dimension and so the risk is minimized. 
Generally, increasing the diameter or length of tubing (i.e. connections) will also contribute to 
band broadening due to the dispersion / Brownian motion through the flow-path. On one hand, 
the velocity of the effluent would drop at the entry of a wider-bore flow path (i.e. changing 
diameters of flow path can affect the velocity of the sample plug) heart-cut loop making the 
heart-cut actuations more error-tolerant. Increasing the diameter of a capillary line would result 
in more space for the sample plug to disperse/ expand and thus reduce the flow rate (i.e. less 
shear). Fortunately, when the 100 µL loop was used for the heart-cut trapping, the peak was 
observable in the second-dimension chromatogram. Throughout the heart-cut trapping 
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protocol, the target analyte peak was trapped with the goal to overfill the heart-cut loop with 
the entire contents of the target analyte trapped. Fortunately, the larger heart-cut loop allowed 
us to trap the analyte in question.  However, a potential concern was whether significant 
dilution or band broadening of the trapped peak will occur when parked in the heart-cut loop. 
An experiment was conducted to observe for the dilution effect on how long the peak can 
remain parked in the loop until it is broad.  A target analyte was injected towards a column for 
the first dimension analysis and was heart-cut towards the second dimension analysis. Prior to 
switching towards the second dimension analysis, the target analyte was left in the loop until 
the first dimension analysis and priming time (further discussed on page 45) were complete; 
once complete, the target analyte eluted out.  A small, albeit significant variation in the 
retention time [RSD 0.5%] of the target analyte was observed during the first dimension 
analysis (i.e. when sample is run through same primary column multiple times). This was of 
concern since the open and close delay times were set prior to the start of the chromatographic 
run involving the heart-cut step. Fortunately, the variation (0.02 minutes) was significantly less 
than the time allowed between the open and close delay functions (1 minute) for the 100 µL 
loop. This experiment not only exhibited the success of heart-cut protocol in trapping a target 
analyte but also exhibited little to no peak broadening within the range of 0.2-0.3 min at most. 
2.2.1 Evaluation of peak properties using the two-dimensional beta-setup 
 
The success of the heart-cut experiment subsequently led to an evaluation of peak 
properties arising from the heart-cut operation.  In order to test for peak broadening, the same 
sample of 2-chloropyridine was run through the first-dimension chromatographic medium 
(C18 HPLC column) with the heart-cut valve set in the bypass mode (i.e., bypassing the heart-
cut loop and sending the sample to the detector). The peak width of the target analyte was 
found to be 0.3 min. Next, the same experiment was performed without the heart-cut valve 
physically being a part of the chromatographic path. The peak width of the same injectable was 
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0.2 min. The peak width variation was judged to be manageable since the detectability of peaks 
by the software remained unaffected with or without the presence of the heart-cut valve in the 
chromatographic path. Peak broadening was a potential concern as the heart-cut valve was 
placed behind the detector and, thus, elongating the flow path through additional capillaries 
and a wider bore loop- these all would contribute towards Brownian motion (longitudinal 
diffusion) of the target analyte's molecules within the flow path. Furthermore, varying the 
diameters of the flow path lines will result in pressure fluctuations throughout the lines and 
may also contribute to peak broadening that may be evidently observed in the output 
chromatogram. The same set of experiments were performed, this time using the first and the 
second dimension setup (i.e., using two identical C18 HPLC columns in accordance with the 
2D-HPLC schematic presented in Figure 10). The peak properties were found to vary in peak 
width, height and symmetry, but showed little variation in the peak area between dimensions 
due to the heart-cut operation (Table 2). However, peaks were found to retain their Gaussian 
shape allowing the integrated software to easily register all analyzed peaks by data processing 
algorithm of the controller software. 
Peak properties First dimension analysis; the heart-cut loop bypassed (min) 
Second dimension analysis; injection 
from the heart-cut loop (min) 
Peak width 0.11 0.21 
Peak area 858.8 868.8 
Peak height 123.3 58.1 
Peak symmetry 0.75 0.37 
Table 2: A comparison of peak properties with and without the heart-cut step included in the 
two-dimensional chromatographic method. 
 Pressure fluctuations, measured by an inline pressure sensor, during the switching of 
the heart-cut (VH) valve were found to be negligible (less than 1 bar) whereas switching of the 
stream selector valve (VS) caused pressure to increase by more than 1 bar leading to small blips 
being registered in the chromatogram during. Ideally, this pressure fluctuation should be 
reduced, and if possible, completely eliminated so the identification of real peaks by the data 
processing algorithm remains unambiguous (i.e. can differentiate between real sample peaks 
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and pressure fluctuations). However, a pressure mitigation mechanism requires physical 
alterations to the chromatographic flow-paths in question. Fortunately, this pressure-mediated 
artefact is small and predictable (i.e., the data processing software could identify the blips based 
on the actuations of VS recorded by the controller software). The heart-cut mechanism was 
tested under various repetitive chromatographic conditions to conclusively identify and 
discount the pressure-related artefacts from the chromatographic analysis. The detector was set 
at a wavelength of 254 nm where all target chemical components were observable at high 
absorbance values; the impact from the pressure fluctuation artefacts were rendered far less 
observable in comparison to the target chemical components in our analyses.  
 
2.2.2 Evaluation of the beta-setup using a Buchwald-Hartwig Amination reaction 
 
 With a functional 2D-HPLC platform in hand, a model reaction was chosen to test the 
heart-cut mechanism.  The reaction chosen for this study was a Buchwald-Hartwig amination 
under flow conditions. Professor Michael Organ from York University developed a flow-cell-
free sampling device that is capable of sampling from a microwave assisted high pressure flow 
reactor. This technology is commonly termed as Microwave-Assisted Continuous-flow 
Organic Synthesis (MACOS).29 The MACOS reactor was first integrated to the 2D-HPLC 
setup using a previously-reported sampling technology.28 Details of this integration process, 
which was comprised of troubleshooting on sampling, sample delivery, and sample preparation 
steps, can be found in the experimental section. Once a suitable sample preparation mechanism 
was in place, attention was turned toward optimizing the model reaction so that monitoring two 
process quality attributes (in this case, product yield and optical purity of a chiral product) 
could take place in a real-life laboratory situation. 
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Scheme 1: Buchwald-Hartwig amination of 2-chloropyridine using a palladium pre-catalyst in 
flow. Filtration enabled –sampling was employed via a 10-port valve with an in-line filter and 
it is a sampling mechanism that was developed for flow synthesis in the Organ lab. 
In this model reaction, 2-chloropyridine (1) was reacted with L-phenyl alanine ethyl 
ester (2) in the presence of a base and a suitable palladium catalyst (Scheme 1). The Pd-PEPPSI 
(Pyridine Enhanced Pre-Catalyst Preparation Stabilization Initiation) pre-catalyst system, 
which was also developed by Professor Michael Organ from York University was proven to 
be a highly efficient pre-catalyst for such reactions.24 In order to monitor the progress of this 
reaction under flow conditions, a reverse-phase chromatographic method using anisole as an 
internal standard was developed (Figure 12). The second-dimension (chiral) separation, of 
product 3, was attempted first using a reverse-phase chromatographic condition using a 
KH2PO4 /K2HPO4 buffer at pH 5.8.  The chromatographic medium (C2) for this dimension was 
a protein-based ES-OVM HPLC column. Unfortunately, chiral separation was found to be 
irreproducible, despite thorough screening of buffer conditions and experimenting with various 
reverse phase solvent systems. The peak from one enantiomer was found to be excessively 
broad, and the peak identification method in the data processing software failed to reliably 
identify the peak. Work on this chiral separation, which was heavily reliant on pH-dependent 
structural behavior protein-based stationary medium, was found to be time-consuming, at least 
 30 
for the purpose of testing the beta-platform. Parallel separation work using a ChiralPAK IA 
HPLC column was successful (resolution: 3.6) using normal phase elution conditions 
(hexane/iso-propanol) (Figure 13). Unfortunately, ChiralPAK IA column, which uses a 
carbohydrate-based stationary phase for chiral separations, cannot tolerate any aqueous 
conditions (i.e. water or any mobile phase composition comprising more than 50% alcohol in 
normal alkane as the primary solvent). This restriction prevented the use of reverse phase 
conditions for the first dimension analysis. Consequently, C1 was switched from the C18 HPLC 
column to a CN HPLC column, which is known to function under normal phase 
chromatographic conditions.  A representative sample of compound 3 with a known optical 
purity was analyzed using the 2D-HPLC setup. The optical purity from the two-dimensional 
beta-setup was compared to that from a Nuclear Magnetic Resonance (NMR) Spectroscopy 
technique using a shift reagent.30 The ratio between two enantiomers was reported as 2:1 by 
NMR. The same ratio from the current beta-setup was found to be 67.58: 32.42 (2.08:1).  
 
Figure 12: First dimension chromatogram of Buchwald Hartwig reaction mixture with anisole 
as the internal standard. 
  
Figure 13: Chiral separation of product 3 via the ChiralPAK IA column under normal phase 
conditions  
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The next step was to integrate the 2D-HPLC setup to a previously reported sampling 
mechanism so that a representative sample could be transferred from the MACOS reactor to 
the 2D-HPLC platform in an automated manner. It is important to note that the model reaction 
involved a transition-metal mediated cross-coupling. The presence of colloidal palladium 
particles in the injection matrix could affect the performance of the analytical column due to 
chelation. The metal ions could ligate to a portion of the analyte to form soluble metal 
complexes, which could have different UV-absorption properties (leading to detection issues) 
and chromatographic affinities (leading to retention time variability). Run-to-run 
reproducibility could potentially deteriorate due to binding of the stationary phase to the metal 
ion. Initially, injections were made directly from the reactor output without any sample 
purification, however run-to-run reproducibly was poor during those experiments. Removal of 
palladium ions from the samples was attempted using an automated liquid-liquid extraction 
(LLE) technique with various palladium scavenging agents. Ultimately, a wash with an 
aqueous solution of tri-sodium ethylenediaminetetraacetic acid (EDTA) solution was found to 
be effective for sample preparation. Relevant details on the sampling and sample preparation 
work can be found in the Experimental section. 
 With a functional sampling and sample preparation strategy for the 2D-HPLC in hand, 
the model Buchwald-Hartwig amination reaction was attempted in flow using three positive-
displacement pumps.  The flow synthesis method comprised of one pump moving reagent 1 
and the base, the second moving reagent 2 and catalyst, and the third moving the internal 
standard, all as solutions in DME at a net flow-rate of 75 µL/min. Cesium carbonate was first 
chosen as the base. A microwave generator, which is a part of the MACOS reactor platform, 
was set to heat the flowed reagents at 75 ͦC. A 33  µL sample was sent from the flow reactor to 
the analytical platform to measure conversion to product 3 and its optical purity. Although the 
sampling mechanism was enabled with slurry handling capabilities, the reagent pumps were 
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not equipped with suitable technology to pump such slurries and cesium carbonate was also 
found to precipitate in the reagent syringe itself. Consequently, delivery of the base to the 
reactor was unreliable. This was also evident from the chromatogram which showed no 
formation of product 3. Soluble sodium phenolate was used as an alternative base; however, 
this base had a poor shelf life (i.e. precipitation occurred in the syringe when the batch of the 
base was more than a day old). Also, there was no observable product formation. Several 
attempts were made using a variety of Pd-PEPPSI pre-catalysts, and different bases. A 
summary of reaction trials can be found in Table 3. Ultimately, a significantly more reactive 
pre-catalyst, (Pd-PEPPSI-iHeptCl(h3-cinnamyl)), which was found to activate at 75 ͦ C under 
flow conditions, was used and 3 was obtained in 78% yield. With product conversion 
information in hand, optical purity of the material was measured from a second injection using 
the heart-cut method. Enantiomeric excess (ee) was found to be very low (<1%). This was 
expected since strong bases like sodium tert-butoxide are known to epimerize the chiral center 
of product 3.  
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Reaction Condition Outcome Possible reason 
Reagents 1, 2, cesium carbonate, Pd-PEPPSI-iPent, 
75 ͦ  C, 75 µL/min flow-rate 
No product Precipitation of cesium 
carbonate in pump 
Reagents 1, 2, sodium phenolate, Pd-PEPPSI-iPent, 
75 ͦ  C, 75 µL/min flow-rate 
No product Instability of sodium 
phenolate under flow 
conditions 
Reagents 1, 2, sodium tert-butoxide, Pd-PEPPSI-
iPent, 75 ͦ  C, 75 µL/min flow-rate 
No product Pre-catalyst may not 
have sufficient time for 
the activation 
Reagents 1, 2, sodium tert-butoxide, Pd-PEPPSI-
iPent with Li-isopropoxide activation, 75 ͦ  C, 75 
µL/min flow-rate 
No product Pre-catalyst may not 
have sufficient time for 
the activation 
Reagents 1, 2, sodium tert-butoxide, Pd-PEPPSI-
iPentCl-o-Picoline, 75 ͦ  C, 75 µL/min flow-rate 
No product Pre-catalyst may not 
have sufficient time for 
the activation 
Reagents 1, 2, sodium tert-butoxide, Pd-
iHeptCl(h3-cinnamyl), 75 ͦ  C, 100 µL/min flow-
rate 
78% conversion 
into a racemic 
product mixture 
Racemization was due 
to the use of a strong 
base 
Reagents 1, 2, sodium tert-butoxide, Pd-
iHeptCl(h3-cinnamyl), 80 ͦ  C, 100 µL/min flow-
rate 
Unstable reaction 
temperature 
Possible interference 
between the heat source 
(microwave) and the 
metal ion in solution 
Table 3: Summary of results from various attempts of the model Buchwald-Hartwig amination 
in flow. 
 The purpose of using the model Buchwald-Hartwig amination reaction was to quickly 
assess whether the multi-dimensional platform could be used to measure two quality attributes 
in parallel and optimize a chemical process that gives a chiral product. The next logical step in 
this direction was to maximize conversion to product 3 by increasing the reaction temperature 
or by reducing the reaction flow-rate. Unfortunately, the temperature of the reactor was found 
to be unstable above 80 ͦ C due to a technical issue with the microwave reactor. An increase in 
palladium pre-catalyst loading, which could also increase the product conversion, led to some 
anomaly in the heating mechanism possibly due to the interference of excessive metal ions 
with microwave. In some cases, the temperature was found to unexpectedly rise within the 
reactor and syringe placed in-line to the microwave reactor. The sampling valve failed to collect 
the contents of the reaction mixture. The hypothesis made was that the valve, which was mostly 
made of stainless steel, may have acted as a heat sink in this case. Lowering the flow-rate was 
also found to be problematic. The reagent pumps, which move all reagents towards a common 
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union, did not work well when the flow-rate was very low. Instead of conducting further 
research to identify the issues relating to the flow reactor technology, a different model reaction 
was chosen, this time using the multi-dimensional platform to move towards a multi-QA 
analysis protocol. 
2.3 Development of the ultimate multi-dimensional chromatography platform for 
multi-QA analysis 
 
A fundamental difference between the two-dimensional beta-platform (described in the 
previous section, Figure 10) and the proposed multi-dimensional platform (Figure 9) stems 
from the ability to re-circulate a portion of the chromatographed effluent post-detection. A 
detailed version of the schematic presented in Figure 9 can be found in Figure 14. The detector 
is no longer the terminal (i.e. after the second dimension of analysis as observed in our beta-
platform) of the chromatographic design. The detector (D) outlet was connected to the heart-
cut valve (VH) instead of to waste (W). Valve VH, in turn, was connected to a set of 
chromatographic media to be used for multi-dimensional analysis. Inter-connectivity of 
modules was changed from the schematic shown in Figure 6 in order to support the concept of 
multiple recycling of chromatographed effluent in the new design. Four of the six available 
flow-paths of the column selector valve (VS) were used. The first flow-path (shown in red) was 
connected to a chromatographic medium (C1), which was responsible for the first dimension 
analysis. The second and the third flow-paths (shown in green and purple, respectively) were 
connected to two chromatographic media (C2 and C3 respectively) via the heart-cut valve (VH). 
Valve VH was equipped with two heart-cut loops (LH1 and LH2, shown in green and purple), 
which could establish fluid communications to C2 via LH1 and to C3 via LH2. LH2 is shown to 
have a fluid communication with C3 in Figure 14. A portion of the effluent from C1 could be 
moved to LH1 in this position of VH by pump P. When valve VH was rotated to the other position 
(shown in the insert of Figure 14), the material in LH1 could be moved towards C2 for analysis 
and another portion of the effluent from C1 could be trapped in LH2. When valve VH was rotated 
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back to its original position (i.e., the position of VH shown in main schematic of Figure 14), 
the second portion in LH2 could be moved toward C3 for analysis.  It is important to note that 
the portion of the effluent from the first dimension analysis that was not trapped in LH1 or LH2 
flowed to waste from either position of VH.  
Upon injection at VI, VS was set to flow the injected sample to C1. The data collected 
during this time constitutes the first dimension analysis. A portion of the first dimension 
effluent was trapped in LH1 until the remaining portion of the first dimension analysis was 
completed using LH2 of VH. Upon completion of the first dimension run, VS was rotated to 
establish fluid communication between pump P and C2. The heart-cut material trapped in LH1 
was sent to C2 for analysis. The data acquired during this time constitutes the second dimension 
analysis. A selected portion of the second dimension stream was isolated in LH2 using a similar 
strategy. Once the chromatographic run for the second dimension analysis was completed, VS 
was rotated to set up a fluid communication between pump P and C3. The material in LH2 was 
then sent to C3 for a third dimension analysis. It is important to remember that VH could channel 
any portion of the effluent from detector D to either of the two loops (green LH1 and purple 
LH2) and recycle the trapped portion either through C2 or C3. For example, if a portion of the 
fluid from the third-dimension stream was to be re-analyzed by C3 again, VH and VS could be 
configured appropriately to do that task. Depending on the purpose of that analysis a new set 
of data could be generated by the detector to obtain a fourth dimension analysis. The entire 
operation was to happen from a single injection at VI. 
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Figure 14: Novel multi-dimensional setup with heart-cut capabilities and priming line. The 
insert shows the second position of the heart-cut valve. Legends: P = HPLC pump, VI=Injector 
valve, VS = Column selector valve, VH = Heart-cut valve, I = Injector port, C1 = First 
dimension chromatographic medium, C2 = Second dimension chromatographic medium, C3 = 
Third dimension chromatographic medium, LI = Injection loop, LH1 = First heart-cut loop, 
LH2 = Second heart-cut loop, D = Detector, W = Waste. 
 To test the entire setup, a sample of Warfarin was injected into valve VI of the new 
design. The first dimension-chromatographic medium (C1) was a CN HPLC column, which 
was suitable for normal phase chromatographic conditions. Two 250 µL loops with wider bore 
size were used as the heart-cut loops to ensure that all of the selected portion of the effluent 
was transferred during the heart-cut process. An identical cyano HPLC column was used as C2. 
A heart-cut protocol (i.e., optimized for open and close delay functions) for the first and the 
second dimension analyses were successfully implemented. Focus then shifted toward the third 
and the fourth dimension analysis. Keeping the objective of chiral analysis in mind, ChiralPAK 
IA was chosen as C3.  Chromatographic conditions (i.e., the mobile phase) for the first two 
dimensional analyses were expected to be significantly different from the one for the chiral 
analysis. It is important to note that only one HPLC pump and one detector were employed for 
the entire multi-dimensional design leading to sharing of flow-paths for the mobile phases in 
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different dimensions of analysis. Switching of chromatographic conditions between any two 
dimensions would not be accurate unless the chromatographic conditions for the dimensions 
in question are identical. In order to ascertain that the chromatographic fluid in the shared flow-
path is in steady state before the start of a particular dimension of analysis, a restricted union 
path was connected to the fourth available flow-path of valve VS (shown in brown in Figure 
14). When a particular dimension of analysis was completed, valve VS was switched to the 
fourth flow-path (i.e., the restricted union path) to drive all effluents from the previous 
dimension of analysis out of the shared flow-path before starting a new dimension of analysis.  
The strategy was verified by comparing retention times of a chosen target analyte (Warfarin, 
in this case) with varied amount of priming time between any two chromatographic 
dimensions. The priming time is defined in our setup as the time required to switch from one 
mobile phase separation method to another without co-elution of the mobile phase that could 
hinder the separation of samples (i.e. it is the time the column selector valve is in fluid 
communication with the restricted union path). The average priming time within the 
operational range of chromatographic flow-rates using the above-mentioned C1, C2 and C3 
HPLC columns was found to be 30 min. Chromatographic methods were developed for the 
achiral and chiral dimension analysis using the cyano and ChiralPAK IA HPLC columns. The 
priming strategy was incorporated in-between dimensions of the multi-dimensional 
chromatographic method to ensure steady states were achieved prior to the start of a new 
dimension. A racemic sample of Warfarin was recycled through C1 (CN HPLC column) and 
three times through C2 (a second CN HPLC column) to examine peak recovery in a four-
dimensional chromatogram (Figure 15). Various peak properties of the control analyte are 
presented in Table 4.  A chosen impurity (methyl m-nitrobenzoate) was added to test the 
performance of the first heart-cut step, sole purpose of which was to purify a targeted peak in 
the injected sample for subsequent analyses. The impurity was carefully chosen such that it 
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does not react with warfarin or any of the starting reagents. Percent recovery between first two 
dimensions (peak areas from row 1 and 2) was found to be 58%. The similar comparison 
between the second to the third (peak areas from row 2 and row 3) and the third to the fourth 
(peak areas from row 3 and row 4) were found to be 68% and 60%, respectively. Overall, on 
an average approximately 60% of a chromatographic peak was recovered between two 
dimensions. A part of this peak loss could be from the inability to capture all of the effluent 
containing the peak of interest during the heart-cut step. The logic in the decision-making 
process of the data processing algorithm is built around the ability to identify a 
chromatographic peak and calculate its purity based on the peak area in the dimension in 
question. Variation in peak areas between dimensions did not factor in the calculations as long 
as the peak properties were in agreement with the peak identification qualifiers set in the data 
processing algorithm. It is also important to note that the signal-to-noise ratio of the fourth-
dimension peak was high enough for the sample to be further recycled if there was an analytical 
need. Peak symmetry was also found to be satisfactory for accurate identification of a target 
peak by the data processing algorithm. 
Warfarin peak 
from various 
dimensions 
Retention 
Time (min) 
Peak area 
(mAu*min) 
Peak 
height 
(mAu) 
Percent 
recovery∆ 
Peak 
symmetry 
s/n ratio 
1st dimension 37.2 1082.19 1036.29 - 1.19 8767.99 
2nd dimension 48.3 632.50 921.03 58 2.93 5898.72 
3rd  dimension 53.1 424.80 479.26 67 1.14 3069.43 
4th  dimension 56.41 255.78 410.88 60 2.90 14477.75 
Table 4: A comparison of peak properties of Warfarin from multiple recycling iterations in the 
second dimension of the multi-dimensional chromatographic design. ∆ Calculated from the 
ratio of peak areas from the first to the second dimension between two consecutive dimensional 
analyses. 
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Figure 15: Chromatogram from multiple recycling of Warfarin for the study of its peak 
properties in various chromatographic dimensions 
 
2.3.1. Evaluation of the multi-dimensional setup using synthesis of Warfarin 
 With the heart-cut protocol for the multi-dimensional setup validated, testing of the 
multi-dimensional setup for the parallel analysis of multiple quality attributes began. Synthesis 
of Warfarin was chosen as a model reaction for this purpose. Warfarin, which is an active 
pharmaceutical ingredient for an anti-coagulant drug CoumadinTM, has one chiral centre in it.31 
The synthesis of Warfarin via an asymmetric Michael Addition reaction is well documented in 
the literature and several chiral catalysts including those derived from amino acid-based 
imidazolidines32 and 1,2-diphenylethanediamine31,33 have been reported in the literature. The 
reaction has been examined largely in batch as the reaction is reported to be problematic in 
flow due to the poor solubility of 4-hydroxycoumarin. The reaction of 4-hydroxycoumarin (4) 
with trans-phenyl butenone (5) in the presence of chiral 1,2-diphenylethanediamine to give 
Warfarin (6) is presented in Scheme 2. Percent product conversion to 6 and optical purity were 
chosen as the two quality attributes to monitor. A multi-dimensional chromatographic method 
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was needed first in order to study the synthesis of product 6 using this multi-QA analytical 
platform. 
 
 
Scheme 2: Synthesis of Warfarin in batch 
2.3.1.1. Development of a multi-dimensional chromatographic method for analytical 
study of Warfarin synthesis 
 
 A racemic sample of product 6 was first used to develop a chromatographic method for 
all four dimensions of analysis.  A mixture of hexanes and iso-propanol (95:5 by volume ratio) 
was found to be optimal for the first two achiral dimensions, which were done using two 
identical cyano HPLC columns. The chiral analyses (the third and fourth dimensions) were 
done with a mixture of hexanes and iso-propanol (80:20 by volume ratio) using a ChiralPAK 
IA HPLC column. The priming strategy was successfully implemented to ensure all three 
HPLC columns were at steady state prior to the start of each dimension analysis. 
As seen during the evaluation of the beta-setup, pressure fluctuations during the 
switching of the column selector valve (VS) were noticeable. To simplify the peak 
identification process by the data-processing algorithm, a time-programmed variable-
wavelength detection method was used. The first dimension analysis was done at 254 nm 
wavelength while the remaining dimensions were analyzed at 214 nm. An external standard 
calibration curve was constructed using the variable-wavelength detection protocol. Once all 
aspects of the chromatographic method were judged satisfactory, an analytical sample from a 
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trial sample from a batch synthesis of 6 was injected to obtain a full four-dimensional 
chromatogram (Figure 16). The portion of the chromatogram representing the first dimension 
analysis showed three peaks wherein the first peak was compound 5 (8.4 min), second peak 
was compound 4 (9.9 min), and the last peak was the chiral product Warfarin (compound 6, 
38.1 min). The HPLC purity (i.e., the percent product conversion to 6) was found to be 17%. 
The portion of the chromatogram representing the second dimension analysis showed a single 
peak of 6 at 45.2 min.  Appearance of the warfarin peak as a single peak confirmed that the 
open and close delay parameters for the first heart-cut step were optimal and the purity of the 
heart-cut sample was satisfactory for a meaningful chiral analysis in later dimensions. The 
verified Warfarin peak was recycled using a second heart-cut step for subsequent chiral 
analyses. Two peaks were observed at 89.7 min and 100.4 min for the two enantiomers of 
Warfarin in the chiral dimension (i.e., the third dimension). The enantiomer at 100.4 min was 
recycled through the chiral column (C3) after a third heart-cut. The targeted enantiomer 
appeared at 121.1 min in the fourth dimension portion of the chromatogram. The ratio of peak 
areas from both enantiomers were found to be equal, which was consistent with the injection 
of the racemic sample. Appearance of a single peak in the fourth dimension portion of the 
chromatogram suggested that there was no on-column degradation of the enantiomer product 
(i.e., no on-column racemization).  
 
Figure 16: A sample multi-dimensional chromatogram from the synthesis of Warfarin 
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2.3.1.2. Reaction optimization for the synthesis of Warfarin using the multi-dimensional 
multi-QA analytical platform 
 
 With satisfactory validation data from the multi-QA setup in hand, a batch reaction for 
the synthesis of product 6 was set up using (1S,2S) -(-)-1,2-Diphenylethylenediamine ((S, S)-
DPEN) as the chiral catalyst according to the reaction condition shown in Scheme 2. The 
presented four-dimensional chromatogram below displays the output results of an aliquot taken 
after 24 hours of the reaction (Figure 17). The product conversion was found to be just 16 % 
with an optical purity of 79 %. This chromatogram proved that the strategy to obtain multi-QA 
data from a single injection using the multi-dimensional setup of Figure 14 is achievable. 
 
Figure 17: Multi-dimensional chromatogram from the synthesis of Warfarin using S, S-DPEN 
as the chiral catalyst. 
A slightly larger scale reaction was set up and aliquots were manually collected from 
time to time to monitor the progress of the reaction (i.e., percent product conversion and optical 
purity) over a week. If the reaction was allowed to stir for a prolonged period of time, the 
reaction could proceed in the forward direction (i.e., higher conversion to product 6), although 
optical purity of 6 could be compromised over time. The ability to obtain multiple number of 
quality attributes could mitigate the risk of losing product purity (e.g., optical purity in this 
case) while monitoring product conversion over time. The multi-QA analytical platform 
 43 
successfully reported both percent product conversions and optical purity from all samples as 
shown in Figure 18. The formation of product 6 was found to increase overtime (approximately 
5% per day) and the product was found to retain its enantiomeric purity (range: 75 - 82 %) in 
the reaction mixture over seven days. 
 
Figure 18: Multi-QA results from the monitoring of Warfarin synthesis using S, S-DPEN as 
the chiral catalyst for 168 h. 
The synthesis of Warfarin was also done using (1R,2R) -(-)-1,2-
Diphenylethylenediamine ((R, R)-DPEN) as the chiral catalyst. As expected, the other 
enantiomer of Warfarin (i.e., the first eluting peak in the third dimension portion of the multi-
dimensional chromatogram), was found to be the major product this time (Figure 19). The 
minor enantiomer (i.e., the second eluting peak in the third dimension portion of the 
chromatogram) was recycled into the fourth dimension to check for on-column racemization 
of the chiral product 6. Further examination on the peak recycling of the first major enantiomer 
in this experiment was conducted in a later experiment and yielded inconclusive results, which 
is discussed on page 47. In this experiment, upon recycling of the minor enantiomer, no 
degradation was observed in the fourth dimension portion of the chromatogram. A similar 
seven-day experiment was also done to monitor the progress of Warfarin synthesis from the R, 
R-DPEN catalyst (Figure 20). 
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Figure 19: Multi-dimensional chromatogram from the synthesis of Warfarin using R, R-DPEN 
as the chiral catalyst. 
 
Figure 20: Multi-QA results from the monitoring of Warfarin synthesis using R, R-DPEN as 
the chiral catalyst for 168 h. 
Once sufficient amount of product 6 was isolated from the scale-up reaction using the 
S, S-DPEN catalyst, product 6 was also purified using conventional preparative scale 
chromatographic techniques.  The purity of compound 6 was confirmed by standard HPLC 
technique and the purified sample was injected directly into the ChiralPAK IA column to 
compare optical purity obtained by the multi-QA HPLC technique to the one obtained from 
the standard one-dimensional chiral HPLC analysis, which is the current state of the art. The 
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results were found to be identical. The optical purity was also determined using NMR 
spectroscopic and polarimetric techniques. Comparison of data are presented in Table 5. 
Stability of the chiral centre in product 6 during off-line purification, which may lead to the 
epimerization, could have been a concern. It is important to note here that preparative-scale 
purification prior to chiral analysis is a standard and mandatory practice since the results from 
available chirality assessment techniques (standard HPLC or polarimetry) are very sensitive to 
the purity of the analyte. In fact, the ability to conduct chiral analysis without incorporating a 
preparative-scale laboratory purification step is one of the principal advantages of the presented 
multi-QA analytical platform. It is also important to note that any chromatographic artefacts 
which may have originated from the first (purification) and the third (analysis) dimension 
chromatographic analyses, were identified in the second and the fourth dimension 
chromatographic analyses by the data processing algorithm to validate analytical 
measurements. 
Analytical technique Chiral purity 
One dimensional HPLC  86 % 
Polarimetry 90 % 
The new multi-dimensional 
multi-QA HPLC 
86 % 
Table 5: Comparison of optical purity from various techniques including the multi-QA 
platform. 
 
An attempt was made to examine the reaction when a reaction condition is changed to 
optimize for the Percent conversion. This experiment was done as additions made to a reaction 
vessel may change the contents of the reaction mixture in a way that upon analysis retention 
time shift and even possible unforeseen impurities or byproducts may be observed.  An attempt 
was made to make Warfarin using 5 mol% of lithium acetate (LiOAc) as an additive according 
to a literature procedure .31 Product conversion from two consecutive batch runs using LiOAc 
were found to be low (18%), but consistent. Enantiomeric excess of product 6 was found to be 
86 %. The chromatogram is shown in Figure 21.  
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Figure 21: Multi-dimensional chromatogram from the synthesis of Warfarin using S, S-DPEN 
as the chiral catalyst using LiOAc as an additive. 
The analyses of all four dimensions were done using the minor enantiomer (i.e., the 
second eluting peak from the third dimension portion of the chromatogram in Figure 19) during 
the experiment with the reaction involving the RR-DPEN catalyst. Recycling of the major 
enantiomer, which was the first eluting peak in the third dimension portion of the 
chromatogram, posed a peak identification issue in the data processing software. Figure 22 
illustrates an example of a multi-dimensional chromatogram when attempts were made to 
recycle the major enantiomer (i.e., the first peak of the third dimension portion of the 
chromatogram). The overlap of peaks occurred between the third and the fourth dimension 
peaks as the fourth dimension heart-cut process was carried out while the column selector valve 
was still in fluid communication with the chiral column responsible for analysis of both the 
third and fourth dimension analysis. Ideally, the workflow of the multi-dimensional method 
was to carry out the execution of one chromatographic dimension at a time (i.e. each dimension 
was to be treated as a separate analysis space where an output QA or verification of an output 
QA is determined). A closer inspection of the schematic in Figure 14 revealed a possible 
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scenario wherein such overlaps may occur. The design presented in Figure 14 did not allow for 
the fourth-dimension run to be delayed until the third-dimension run was completed. When 
valve VH was rotated to isolate the Warfarin enantiomer in question in LH2 during the third and 
the final heart-cut (Figure 14), pump P immediately established fluid communication with LH2 
(Figure 14) and commenced the fourth dimension run as soon as the third heart-cut step was 
completed. In other words, the rotation of VH to complete the third heart-cut task was 
responsible for the immediate start of the fourth dimension.  In many cases, this phenomenon 
would not necessarily pose a chromatographic issue (i.e., the overlap of peaks from two 
different dimensions), especially when the last two dimensions involve chiral resolution. 
Separation of chiral peaks are generally viewed as difficult and the distance between two 
enantiomeric peaks (i.e., the chiral resolution of peaks) are generally small. In certain cases, 
when the chiral resolution is fairly large and the retention time of the first eluting peak is 
significantly small, such overlaps may result. The phenomenon is further explained pictorially 
in Figure 23. 
 
Figure 22: Multi-dimensional chromatogram from the synthesis of Warfarin showing overlap 
of peaks when the second eluting enantiomer from the third dimension was subjected to heart-
cut.  
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 The middle chromatogram in Figure 23 shows the time at which a heart-cut step took 
place (the vertical line). The top chromatogram represents the chiral resolution of a mixture 
containing both enantiomers without any heart-cut step. If there is no provision to park the 
heart-cut sample, the first eluting peak from the chiral separation, if recycled, may re-elute 
before the elution of the second peak from the chiral separation (i.e., top chromatogram). This 
is because the retention time of the first eluting peak in the top chromatogram is significantly 
low and the distance (by time) between both peaks (top chromatogram) is significantly large. 
First step towards rectifying this matter was to identify all three peaks with certainty beyond 
the second dimension portion of the multi-dimensional chromatogram. Once the peaks were 
correctly identified, elution of appropriate peaks can be delayed to eliminate overlapping of 
peaks. An example from a real chromatogram is shown in segment A of Figure 24, where such 
an overlap of peaks between 105 and 107 minutes were registered. One of the two peaks in the 
overlapping zone represents the recycled peak for the fourth dimension. The design of the 
multi-dimensional setup was slightly modified to examine if one of the peaks can be delayed 
for unambiguous identification of peaks for the multi-dimensional analysis. Figure 25 
illustrates the modified multi-dimensional design.  
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Figure 23. A schematic comparison of the third and the fourth dimension chromatograms when 
earlier eluting peak from the third-dimension chromatogram was recycled for the fourth 
dimension analysis. A: A schematic presentation of the third dimension chromatogram without 
the heart-cut step for the fourth dimension analysis. B: The third and the fourth dimension 
chromatograms from the heart-cut done using the multi-dimensional design presented in Figure 
12. C: The third and the fourth dimension chromatograms using options to park the heart-cut 
peak until the third dimension analysis is completed. 
 
Figure 24: a) Multi-dimensional chromatogram from the synthesis of Warfarin using designs 
without the delay valve (VD) where peak 1 at 92.7 min is our first eluting enantiomer that was 
recycled and found at 105.5 min and peak 2 at 107 min is our second eluting enantiomer  b) 
Multi-dimensional chromatogram from the synthesis of Warfarin using designs with the delay 
valve (VD) where peak 1 at 92.7 min is our first eluting enantiomer that was recycled and found 
at 115.3 min and peak 2 at 107 min is our second eluting enantiomer   
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A six-port valve two-position valve (VD), in which a sample could be parked for a 
period of time until the previous dimension run is completed, was included downstream of C3 
(Figure 25). This delay valve (VD) could have been put between D and VH to park a 
chromatographic peak immediately after its detection. However, the swept volume of the flow-
path between the detector D and VH was a critical parameter that dictated open and close delay 
time functions. Alteration of this flow-path may require some additional optimization, which 
could take some time, in the heart-cut firmware. For this reason, the flow-path between D and 
VH was kept untouched during the preliminary investigation of peak parking methods. During 
the third dimension analysis, valve VD, which was also equipped with a peak parking loop (LP), 
was kept in the valve-position shown in Figure 25. After the first eluting peak was recycled in 
C3, the effluent carrying the peak was delayed in LP until the third dimension run was 
completed. The timing of this particular peak capture in LP was accomplished by trial and error. 
No automation was planned for this particular step using this design. The trapped peak in LP 
was ultimately released after the third dimension analysis and flowed to detector D using the 
fourth available flow-path of valve VS (shown in pink in Figure 25) to obtain an overlap-free 
third dimension analysis (segment B of Figure 25). Not all of the targeted peak was delayed in 
the elution order. The purpose of this exercise was to examine if the peak parking strategy 
could be accurately executed (i.e., precisely targeting a peak from an overlapped 
chromatographic region) using the current firmware.  It is also important to note that the 
retention time of the targeted peaks vary from run to run due to the continuing modifications 
made in the hardware and the firmware of the current design. The order in which the peaks 
appear in all four dimensions of the multi-dimensional chromatogram is, however, predictable. 
The retention time labels on the chromatogram were generated by the data processing software 
based on a time-counter referenced to the time of injection at VI. Retention times for the 
subsequent dimensions were found to be consistent based on the actuations of VS, VH, and VD. 
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The retention time labels on the chromatogram were not used to track peaks since the controller 
software was capable of tracking peaks from all dimensions using the valve actuation 
information within the software. Ultimate objective of the project would involve actuations of 
all chromatographic valves based on a live feed from the detector. In that case, tracking of 
chromatographic peaks based on valve actuation information within the software could be 
accomplished. 
 
Figure 25: Chromatographic design used to investigate the peak-overlapping scenario. 
Legends: P = HPLC pump, VI=Injector valve, VS = Column selector valve, VH = Heart-cut 
valve, VD = Delay valve, I = Injector port, LI = Injection loop, LH1 = First heart-cut loop, LH2 
= Second heart-cut loop, LP = Delay loop, C1 = First dimension chromatographic medium, C2 
= Second dimension chromatographic medium, C3 = Third dimension chromatographic 
medium, D = Detector, W = Waste. 
2.3.1.3. Reaction optimization for the synthesis of Warfarin in flow using the multi-
dimensional multi-QA analytical platform 
 
 A prospect of using the multi-QA platform for flow synthesis of Warfarin was also 
explored. Scheme 3 shows the flow condition in which reagent 4 and 5 were flowed from two 
separate positive-displacement pumps to a union that was connected to a flow reactor equipped 
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with a sampling device. The reaction was flowed at two different flow-rates. In both cases, 
conversion to product 6 was very low (Table 6). Although optical purity of the output was not 
high, the chromatographic data from the multi-QA analytical setup proved that the parallel 
analysis of multiple process quality attributes is possible, even when a very low quantity of the 
sample is available for analysis. 
 
Scheme 3: Synthesis of Warfarin in flow carried out through a microwave reactor upstream 
from a 10-port sampling valve coupled with in-line filtration capabilities for sampling of 
heterogeneous mixtures. The sampling mechanism for flow synthesis was developed in the 
Organ lab. 28 
Flow Rate 
(µL/min) 
Residence 
time (min) 
Enantiomeric 
excess (%) 
Conversion to product (%) 
25 60 72 4 
75 20 66 2 
Table 6: Results from the synthesis of Warfarin in flow 
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3. Conclusion 
 In the past, chemists would optimize a reaction one QA at a time, meaning that they 
would initially screen through various input process parameters to optimize for percent  
conversion of the reaction. Once that QA is optimized for, the chemist would then follow up 
to optimizing the reaction to enhance the target product’s purity. However, there is no clear 
relationship between both percent conversion and optical purity, thus optimizing for one QA 
at a time may result in dwindling the second QA. This form of optimization and process 
development faces an inherent risk where potential bias of one QA over the other may occur. 
In response to this inherent risk, several industries couple process optimization protocols with 
PAT tools capable of monitoring the state of the reaction at various points of time. Furthermore, 
the PAT tool offers analysis of the reaction mixture where desired QAs can be attained. A new 
multi-dimensional PAT tool with heart-cut capabilities was developed in the Organ lab capable 
of analyzing for multiple QAs. A beta-platform was constructed comprising of two dimensions 
for analysis of two QAs, % conversion and optical purity. The beta platform was coupled to an 
in-house developed flow system called MACOS with a novel sampling valve coupled with in-
line filtration capabilities. The Buchwald Hartwig Amination reaction was chosen as the model 
reaction and provided valuable insight into the machinations of the heart-cut protocol and how 
to prevent co-elution of the mobile phase through the addition of a priming line. The novel 
multi-dimensional tool’s capabilities were tested on an asymmetric model reaction, the 
synthesis of Warfarin. Integrated with the multi-dimensional and heart-cut protocol was a novel 
analytical method called multi-QA analysis that was capable of analyzing for % conversion 
and optical purity along with in-line verification of HPLC purity and enantiomer stability. The 
unique ability of recycling a targeted chromatographic peak through the same or different 
chromatographic media multiple times can play an important role in parallel analysis of various 
critical and essential process quality attributes. Artefacts from various laboratory purification 
techniques can be avoided since the new design does not require any off-line purification means 
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of injectable into the HPLC or either chromatographic dimension. This can be a significant 
advantage in chiral drug synthesis. Any chromatographic artefact from the analytical process 
itself can also be identified and, possibly quantified or eliminated in future generation of the 
presented design. Future generations of the multi-QA design could be also equipped with a 
better pressure mitigation strategy towards a complete PAT-solution for chiral drug 
manufacturing.  
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4. Experimental 
 
4.1. General description of the experimental setup 
Two-dimensional (beta) and multi-dimensional chromatography setups were built from an 
Agilent 1260 HPLC system. Additional valves were purchased from Vici Valco Instruments 
Co. Inc. and CTC analytics AG for the modification of the Agilent single-dimensional 
chromatography system into the ultimate multi-QA analytical setup (Figure 25). Details of the 
analytical setups can be found in section 4.1. Sampling was done using a previously reported 
technique, which is termed as Information-based Rapid & Intelligent Sampling (IRIS). 
Analytes from the IRIS system (i.e. filtration-enabled sampling via a 10-port valve with an in-
line filter)28 were delivered to a Gerstel MPS (Multi-purpose sampler) auto-sampler for 
automated sample preparation and injection. 
A controller software developed in-house was used to coordinate actuations of all devices for 
the chromatographic setup. Details of the controller software can be found in section 4.2. 
Performance of the analytical setups were tested under flow as well as batch conditions. The 
experimental details of the batch and the flow reactions can be found in section 4.3. 
 
4.1.1 Experimental details pertaining to 2D-HPLC (beta) and multi-D HPLC setup 
 
Two-dimensional beta-setup was constructed in accordance with Figure 7 shown in the 
previous section. Multi-dimensional setup, which was built to test the ultimate multi-QA 
analysis, was set up as shown in Figure 25 in the previous section. 
HPLC systems comprised of a sampling module, an autosampler, which was 
responsible for sample delivery and sample preparation, and a chromatography module. The 
chromatography module comprised of an HPLC pump, a detector, and multiple 
chromatographic media (HPLC columns) connected to a set of two-position valves (column 
selector valve VS, and heart-cut valve VH). Six basic steps were executed from the controller 
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software to complete the entire analytical task. They are: sampling, sample delivery, sample 
preparation, injection, chromatography analysis, and data-processing.   
4.1.2. Experimental details for sampling 
Sampling and sample preparation from the batch synthesis of Warfarin reactions were 
done manually. A 33 µL aliquot was taken from the reaction mixture and diluted with 1467 µL 
of Dioxane HPLC-grade in a glass vial. The 1500 µL of analytical sample was placed on a tray 
and injected using an 80 µL injector syringe mounted on the Gerstel auto-sampler. Typically, 
a 10 µL of the analytical sample was injected for chromatographic runs.  
Sampling from the flow reaction was done using a 10-port sampling valve coupled with 
in-line filtration capabilities.28 This valve, which was integrated to the Gerstel autosampler, 
comprised of two ten-port valves.  A schematic of sampling system is presented in Figure 23. 
The first valve (VIRIS1), which was purchased from CTC Analytics [Model # 03-01A], was 
equipped with an inline filter (F) and a sampling loop (LS). Filter F was cleaned by a positive-
displacement pump (PF), which was purchased from New Era Pump Systems, Inc. [Model # 
NE-1000]. VIRIS1, which was controlled from the controller software using a proprietary multi-
position algorithm, was connected to a flow reactor (R). The second valve (VIRIS2), which was 
equipped with an internal standard delivery loop (LI) and an air-sandwich delivery loop (LA), 
was in fluid communication with VIRIS1. This valve was also purchased from Vici Valco 
Instrument Co. Inc. [Model # 12X-0010H]. Two positive-displacement pumps (PI and PA), 
which were purchased from New Era Pump Systems Inc [Model # NE-1000], were used to 
introduce 100 µL of an internal standard solution and an air-plug in the IRIS sampling line. A 
small plug of air was used to transport analytical samples from LS to the multi-QA analytical 
platform (A); the air acted as a sweep to ensure entire contents of the sample loops were 
delivered towards analysis regardless of viscosity differences between diluents. A fourth 
positive-displacement pump (PD), which was purchased from Gerstel GmbH, was operated 
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from the auto-sampler controller for the delivery of the analytical plug to analysis, A. The 
controller software of the multi-QA platform sent necessary signals to the auto-sampler and 
the sampling system to isolate a 33 µL of the effluent from reactor R in LS and deliver the 
trapped sample to the multi-QA platform through a sample delivery mechanism, which is 
described in the next section. 
 
Figure 26: Sampling system for collection and transfer of samples from a flow reaction. 
Legends: R = Flow reactor, C = Bulk product collection module, A = Multi-QA analytical 
system, VIRIS1 = Filtration-enabled sampling valve, VIRIS2 = Internal standard and air-sandwich 
valve, F = Inline filter, LS = Sampling loop, LIn = Internal standard loop, LA = Air-sandwich 
loop, PF = Filter back-flush pump, PI = Internal standard pump, PA = Air supply pump, PD = 
Sample delivery pump, N = Injector syringe, W = Waste 
 
 
4.1.3. Experimental details for sample delivery 
 
 The sample delivery mechanism was only used during the analysis of samples from the 
flow reactor (R). For batch reactions, samples were manually placed on the sample tray of the 
auto-sampler. 
 As mentioned in the previous section, a 33 µL of analyte was extracted from the flow 
reactor using VIRIS1 and moved by pump PD to an injector syringe (N) mounted on the auto-
sampler. The auto-sampler injector syringe (N) was equipped with a side-port, which could 
establish fluid communications between injector syringe N and sampling loop LS of valve 
VIRIS1 of the IRIS system through a sample transfer line. During sample delivery, the controller 
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software sent necessary signals to the auto-sampler controller to move the injector syringe 
plunger away from the side-port (Figure 27). A portion of the fluid (1100 µL)  in the sample 
transfer line was first sent to waste using the auto-sampler. The next 1500 µL segment of the 
fluid in the sample transfer line was collected in a sample vial for analysis. A 2000 µL segment 
of fluid in the sample transfer line was sent to waste to reduce carry-over. 
  
Figure 27: Sample delivery system for flow and batch. Legend: VIRIS1=IRIS Sampling valve, 
SP=Syringe plunger, SI= Injector Syringe, N=Injector Needle, P= Side port 
4.1.4. Experimental details for sample preparation 
 
All sample preparation tasks for sampling from batch reactions were done manually. Sample 
preparation for flow sampling, which was done using the Sampling system, was executed from 
the Gerstel auto-sampler. Analytical samples were prepared using two sample preparation 
functions.  
Simple dilution of the analytical sample, which was used for reactions not containing 
any metal ions, was achieved by controlling the volume of the transport solvent that also acted 
as the diluent. All vials used in reactions requiring simple dilutions without extraction, were 
diluted to 1500 µL. 
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Liquid-liquid extraction (LLE) technique was used for analytical samples that require 
removal of metal ions or any other chemical agents, which could harm the analytical system. 
During LLE, analytes were delivered to a 10 mL sample vial by the IRIS system using ethyl 
acetate as the transport solvent. The auto-sampler was used to deliver 1.5 mL of an aquous 
solutiuon of tri-sodium EDTA to the same vial. LLE was done using a programmable agitator 
device mounted on the auto-sampler. Agitation was done at 250 rpm for 1 min. Upon 
completion of the agitation, the biphasic mixture was allowed to settle for 1 min and the injector 
syringe was used to make 10 µL injection to the chromatography platform. 
4.1.5. Experimental details for chromatography analysis 
A schematic of the latest analytical platform is shown in Figure 25. The injector valve 
(VI), which was a six-port two-position CTC valve with a vertical injection port (I), was 
mounted on the auto-sampler. Valve VI was equipped with a 20 µL injection loop (LI), and 
connected to a column selector valve (VS), which was a fourteen-port six-position stream 
selector valve and purchased from Agilent Technologies. Valve VS was in fluid communication 
with a ten-port six-position heart-cut valve (VH), which was purchased from Vici Valco 
Instruments Co. Inc. A six-port two-position delay valve (VD), which was purchased from Vici 
Valco Instruments Inc. Co., was in fluid communication with valve VS and VH.  An Agilent 
1260 HPLC system with a built-in vacuum degasser was used as the chromatography system. 
Quaternary HPLC pump of the chromatography system was connected to valve VS, which was 
also in fluid communications with three HPLC columns (C1, C2, and C3) hosted in an Agilent 
1290 thermostatted column compartment (TCC). An Agilent 1260 diode array detector (PDA) 
was used as the detector. All chromatographic modules were interconnected in accordance with 
Figure 22 by stainless steel tubing of 0.03˝ internal diameter. Waste lines were connected by 
PEEK tubing (internal diameter: 0.004˝). 
In the two-dimensional beta-platform, first-dimension column (C1) was a 2.1 mm x 150 
mm Poroshell C18 column (particle size: 2.7 µm), which was purchased from Agilent 
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Technologies. The second-dimension reverse phase column (C2) was a 2 mm x 150 mm chiral 
column with an ES-OVM column (particle size: 5 µm), which was also purchased from Agilent 
Technologies. The mobile phase used in the first dimension comprised of a mixture of 
acetonitrile and water, and the mobile phase used in the second chiral dimension comprised of 
a Gomori buffer (KH2PO4/K2HPO4) at pH 5.8, acetonitrile, and water. HPLC grade acetonitrile 
and water were purchased from Millipore Sigma. For normal phase chromatography using the 
two-dimensional beta-setup, a 4.63 mm x 150 mm Poroshell CN columns (particle size: 5 µm), 
which was purchased from Agilent Technologies, was used. 
In the multi-dimensional HPLC setup, the first-dimension column (C1) was a 4.63 mm 
x 150 mm Poroshell CN column (particle size: 5 µm). The second-dimension column was a 3 
mm x 50 mm Poroshell CN column (particle size: 2.7 µm), which was also purchased from 
Agilent Technologies. The third-dimension column (C3) was a 10 mm x 250 mm chiralPAK 
IA column (particle size: 5 µm), which was purchased from Chiral Technologies Inc. The 
mobile phase used across all three dimensions comprised of a mixture of HPLC grade hexanes 
and iso-propanol, which were purchased from Millipore Sigma. Shown below are two tables 
presenting important parameters in the method development for multi-QA analysis of 
Warfarin. 
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Separation Method Total Run Time  170 min 
Column 
Gradient Solvent Gradient 
Time 
(min) Column 
Time 
(min) 
Solvent 
A (%) 
Solvent 
B (%) 
Solvent 
C (%) 
Solvent 
D (%) 
Flow rate 
(mL/min) 
Pressure 
(bar) 
0 4 0 0 0 5 95 0.5 600 
42 5 55 0 0 5 95 0.5 600 
55 3 60 0 0 20 80 0.5 600 
80 2 80 0 0 20 80 0.5 200 
140 3 140 0 0 20 80 0.5 200 
  145 0 0 5 95 0.5 600 
Table 7: A multi-QA analysis separation method developed for Synthesis of Warfarin in batch 
Legend: Column 4 is the first dimension CN column, Column 5 is the second dimension CN 
column, Column 3 is the priming line, Column 2 is the third dimension ChiralPAK IA column. 
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Heart-cut Method Enabled Starting Position at A 
Number of 
2D Recycle 0 
Run Time 
1D (s) 2520 Wavelength Change 
Number of 
3D Recycle 1 
Run Time 
2D (s) 4800 Time (s) 2040 
  Open Delay (s) 
Close Delay 
(s)     
1D 2241 60     
2D 2894 60     
3D-RCY 6414 60       
Table 8: A multi-QA analysis heart-cut method developed for Synthesis of Warfarin in batch 
Legend: 1D= heart-cut sequence from the first dimension towards the second dimension, 2D= 
heart-cut sequence from the second dimension towards the chiral dimension, 3D-RCY= heart-
cut recycle sequence in the chiral dimensions, Run time 1D= run time of first dimension, Run 
time 2D= starting time of chiral dimension, Wavelength change= time at which detection 
wavelength is changed.  
 
4.1.6. Experimental details for data processing 
Raw analytical data acquired from the Agilent detector was processed by Chromeleon 
software from Thermo-Fisher Scientific. The processed data was relayed to the controller 
software of the multi-QA platform for decision-making purposes. Peak identification criteria 
were tested first in the data processing method of Chromeleon chromatography data system 
(CDS). The criteria were later embedded in the controller software through Chromeleon 
software development kit (SDK). Various peak parameters (e.g., peak area, signal-to-noise 
ratio, peak symmetry, baseline, etc.) were used to build a custom peak qualifier method for 
appropriate identification of relevant chromatographic peaks in the multi-dimensional 
chromatogram. A team of engineers were responsible for the development of the peak 
identification strategy. Purpose of this project, which was discussed in this thesis, was to design 
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and test the chromatographic setups using the peak identification strategy. Definitions of peak 
properties are described below: 
Peak Asymmetry (AS): a factor used to determine whether a peak is tailing (if Asymmetry is 
greater than 1) or fronting (if Asymmetry is less than 1). 
𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛	1:	𝐴- = 𝑅𝑊1% + 𝐿𝑊1%2 ∗ 𝐿𝑊1% 	𝑜𝑟	𝐴- = 𝑅𝑊89%𝐿𝑊89%  
 
Figure 28: A schematic depicting the Peak Asymmetry Factor Calculation. Legend: RW5% = 
Right peak width in 5% of the peak height, LW5%= Left peak width in 5% of the peak height 
and RW10%= Right peak width in 10% of the peak height, LW10%= Left peak width in 5% of the 
peak height 
Peak Recovery: a factor used to quantify the heart-cut transfer efficiency of a target peak from 
one dimension to the other. 
𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛	2:	%𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = 𝑃𝑒𝑎𝑘	𝑎𝑟𝑒𝑎	𝑜𝑓	𝑡𝑎𝑟𝑔𝑒𝑡	𝑎𝑛𝑎𝑙𝑦𝑡𝑒	𝑃𝑒𝑎𝑘	𝑎𝑟𝑒𝑎	𝑜𝑓	ℎ𝑒𝑎𝑟𝑡𝑐𝑢𝑡	𝑎𝑛𝑎𝑙𝑦𝑡𝑒 ×100% 
  
Peak width: a time-based factor that provides a measure of the base width of a peak and 
qualitative assessment of the peak broadness 
Resolution: a measure of separation efficiency between two peaks (generally R>1.5 is deemed 
sufficient) 
𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛	3: 𝑅 = 2 𝑡GHIJK8 − 𝑡GHIJKM𝑊HIJK8 +𝑊HIJKM  
 
where tRpeak1= retention time of the first eluting peak, tRpeak2= retention time of the second 
eluting peak, Wpeak1= peak width of the first eluting peak, Wpeak2= peak width of the second 
eluting peak. 
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Figure 29: A schematic depicting the Peak Width of a chromatogram peak 
Analytical data from the Chromeleon CDS was used to calculate Percent conversion to product 
using a mathematical formula shown below. This number was generated automatically by the 
controller software for making decision on a chemical reaction condition. 
𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛	4:%𝐶𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 = 𝐹𝑖𝑛𝑎𝑙	𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛	𝑜𝑓	𝑠𝑡𝑎𝑟𝑡𝑖𝑛𝑔	𝑚𝑎𝑡𝑒𝑟𝑖𝑎𝑙𝐼𝑛𝑖𝑡𝑖𝑎𝑙	𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛	𝑜𝑓	𝑠𝑡𝑎𝑟𝑡𝑖𝑛𝑔	𝑚𝑎𝑡𝑒𝑟𝑖𝑎𝑙 ×100% 
 
Optical purity was measured based on Enantiomeric excess (%ee), which was calculated using 
the following formula: 
𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛	5:%𝑒𝑒 = 𝑅 − 𝑆𝑅 + 𝑆 ×100% 
Data for the Percent conversion to product calculation was generated using an external 
standard calibration curve for the synthesis of Warfarin. 
  
Figure 30: External Standard Calibration Curve of Warfarin 
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Data for Product yield was calculated using an internal standard calibration curve for the 
analysis of flow samples from a Buchwald-Hartwig reaction. 
 
Figure 31: Internal Standard Calibration Curve of Product 3 
4.2. Development of the controller software 
 The system controller, which ultimately controls all hardware of the entire multi-QA 
setup, is a beta-version and developed in-house by a team of engineers. The auto-sampler, 
which was controlled from Maestro software platform of Gerstel GmbH, was integrated to the 
HPLC system, which was controlled by ChemStation software from Agilent Technologies. 
Instructions for all analytical tasks (from injection to detection) were sent to a job queue inside 
Chromeleon software, which, in turn, relayed that information to the auto-sampler and HPLC 
controllers. The in-house system controller had direct controls over the IRIS system, which 
was responsible for sampling and sample delivery tasks. Valves VH and VD were also 
controlled by the system controller itself. Figure 32 shows a summary of software hierarchy to 
execute the entire multi-dimensional chromatography task. 
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Figure 32: Workflow of software commands from the in-house system controller to various 
synthetic and analytical modules. 
 
4.3 Multi-QA Analytical Protocol  
 
Figure 33: Image of the Heart-cut valve integrated in line to the Column selector valve 
 
 Shown below are detailed step by step animated images of both the entire multi-QA 
analytical protocol via the novel multi-dimensional analytical platform along with the step-by-
step valve heart-cut valve actuation protocol between dimensions.  
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Figure 34: First dimension Analysis through C1. Legends: P = HPLC pump, I = Injector, C1 = 
Chromatographic medium for the first dimension, C2= Chromatographic medium for the 
second dimension, C3= Chromatographic medium for the third dimension, VH = Heart-cut 
valve, D = Detector (DAD), W = Waste 
 Sample injection is facilitated through the injector valve VI and is directed to the 
column selector valve VS that is in fluid communication with our first column C1 for first 
dimension analysis and resolution of the reaction mixture. The output QA from the first 
dimension analysis is HPLC purity or if chromatogram was run in-line with a calibration curve 
of the reaction mixture then the % conversion is attainable.  
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Figure 35: Second dimension Analysis through C2. Legends: P = HPLC pump, I = Injector, C1 
= Chromatographic medium for the first dimension, C2= Chromatographic medium for the 
second dimension, C3= Chromatographic medium for the third dimension, VH = Heart-cut 
valve, D = Detector (DAD), W = Waste 
 The boxed red peak in the first dimension chromatogram is our target chiral product 
requiring further analysis on its optical purity. Prior to optical purity measurement (i.e. chiral 
resolution), the target red peak was heart-cut via the heart-cut valve VH towards the second 
column C2 (same stationary phase as C1) to ensure the injectable towards chiral analysis is 
sufficiently pure.  
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Figure 36: Third dimension Analysis through C3. Legends: P = HPLC pump, I = Injector, C1 
= Chromatographic medium for the first dimension, C2= Chromatographic medium for the 
second dimension, C3= Chromatographic medium for the third dimension, VH = Heart-cut 
valve, D = Detector (DAD), W = Waste 
 Once second dimension analysis is complete and has concluded that target analyte is 
sufficiently pure (i.e. single peak is observed) the analyte is heart-cut once more through the 
heart-cut valve and is directed towards the chiral column C3. In the chiral column, the 
isolated chiral sample will resolve down to its two enantiomers wherein the optical purity / 
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enantiomeric excess can be determined. 
 
Figure 37: Fourth dimension Analysis through C3. Legends: P = HPLC pump, I = Injector, C1 
= Chromatographic medium for the first dimension, C2= Chromatographic medium for the 
second dimension, C3= Chromatographic medium for the third dimension, VH = Heart-cut 
valve, D = Detector (DAD), W = Waste 
 To ensure no interconversion between both resolved enantiomers has occurred on-
column, one of the two enantiomers was recycled through the heart-cut valve once more 
towards C3.  
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Figure 38: Heart-cut valve actuation protocol across all four dimensions. Legends: P = HPLC 
pump, C1 = Chromatographic medium for the first dimension, C2= Chromatographic medium 
for the second dimension, C3= Chromatographic medium for the third dimension, VH = Heart-
cut valve, D = Detector (DAD), W = Waste 
 Shown above is a step by step schematic of the valve actuation protocol used to 
facilitate heart-cut across all dimensions through our multi-QA analytical protocol. The open 
delay time is set prior to heart-cut implementation at this registered time the flow path 
towards the loop is open to allow for the analyte to enter, and then a close delay time is 
registered to close the flow path and trap the analyte in the heart-cut loop of interest. The 
valve is actuated accordingly to ensure entry and exit of the analyte towards the target loop of 
interest (i.e. dependent on which column or dimension of analysis the analyte is transferred 
towards). For the heart-cut to be facilitated, a preliminary injection of the reaction mixture 
must be facilitated to obtain a measure of the target analyte’s retention time and peak width 
(Baseline to baseline time measurement of a peak). Based on this information, the size of the 
heart-cut loop should be set accordingly to accommodate the volume of the target analyte 
peak in the event the heart-cut is facilitated with the aim to trap the entire contents of the 
peak (i.e. which was the case in our setup). 
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4.4 General description of the synthetic setup 
The synthesis of Buchwald-Hartwig amination reaction was done in flow. Three 
positive-displacement pumps (purchased from New Era Pump Systems, Model # NE-1000) 
were fitted with 12 mL plastic syringes containing 10 mL of reagent 1 and base, 10 mL of 
reagent 2 and catalyst, and 10 mL of internal standard, anisole. Individual flow-paths from the 
syringes were connected to a common union, which was in fluid communication to a 1 mL 
glass reactor. The glass reactor was placed inside a flow microwave reactor, which was 
purchased from a company formerly known as WaveCraft AG [Model # Arrhenius I]. The 
microwave reactor was controlled from an in-house controller, which was integrated to the 
Microwave, WaveCraft controller. The reaction mixture was flowed from the reactor to a bulk 
product collector via the IRIS system as shown in Scheme 1. 
In contrast to the Buchwald Hartwig amination reaction, the synthesis of Warfarin was 
done in batch as shown in Scheme 4. To a round-bottom flask equipped with a magnetic stir-
bar were added 4-Hydroxycoumarin (162 mg, 1mmol), acetic acid (572 µL, 10 mmol), 
benzylideneacetone (175 mg, 1.2 mmol), and catalytic amounts of either (1S, 2S) -(-)-1,2-
Diphenylethylenediamine ((S, S)-DPEN) (11 mg, 5 mol%) or (1R, 2R) -(+)-1,2-
Diphenylethylenediamine ((R, R)-DPEN) (11 mg, 5 mol%) in 2 mL 1,4-Dioxane at room 
temperature. The reaction mixture was allowed to stir at room temperature for 24 hours. 
Reaction progress was monitored by HPLC (95 Hexane: 5 2-Propanol) as described above. A 
33 µL of aliquot was taken from the reaction mixture every 24 hours and diluted with 1467 µL 
of 1,4-dioxane in a 1500 µL sample vial. The sample vial was placed on the tray of the Gerstel 
Autosampler for HPLC injections. 
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Scheme 4: A schematic of the synthesis of Warfarin in batch 
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4.5 Aqueous Work-up of Warfarin for NMR and Polarimetry 
 
 4-Hydroxycoumarin (162 mg, 1mmol), acetic acid (572 µL, 10 mmol), 
benzylideneacetone (175 mg, 1.2 mmol), and catalytic amounts of either (1S, 2S) -(−)-1,2-
Diphenylethylenediamine ((S, S)-DPEN) (11 mg, 5 mol%) or (1R, 2R) -(+)-1,2-
Diphenylethylenediamine ((R, R)-DPEN) (11 mg, 5 mol%) were added to an oven-dried flask. 
1,4-Dioxane (2mL) was then added and the mixture stirred at room temperature for 24 hours. 
The Reaction progress was monitored by Thin Layer Chromatography (TLC) (5% Methanol: 
95% Dichloromethane). Once complete, the reaction mixture was filtered, and extracted with 
ethyl acetate. The combined organic phases were dried with anhydrous sodium sulfate, filtered, 
and the solvent evaporated. The crude product was then purified by column chromatography 
(Methanol/Dichloromethane) to give warfarin as (60 mg, 20%). 
 The Flash chromatography was performed through a Biotage using a SNAP-50g silica 
gel cartridge. TLC was carried out on silica gel pre-coated glass plates with detection by UV 
light. NMR analyses for Warfarin were recorded in DMSO-d6 at 400 MHz via an available 
Bruker NMR instrument. Polarimetry was carried out using a NaD lamp at a single wavelength 
of 589nm for detection (path length=1dm).  For Polarimetry analysis, a 3.3 mg/1mL Warfarin 
solution in 2-propanol was prepared and taken for quantitative analysis of its observed rotation.  
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